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Rheumatoid arthritis (RA) is a chronic inflammatory disease that mostly affects peripheral 
joints but may have systemic manifestations, potentially resulting in irreversible joint 
damage.1,2 RA may present at any age, and the disease is more common in women than in 
men. The global prevalence of RA is estimated to be rather stable during the past decades, 
ranging from 0.5-1%.1,3 A few decades ago, many patients had prognostically unfavourable 
disease, were continuously suffering from pain and stiffness, and faced functional disability 
and progressive joint destruction. Extra-articular manifestations of the disease included 
involvement of internal organs, which interfered with general wellbeing and resulted in 
frequent hospitalisations and increased mortality.4-6 During the last decades, major changes 
have impacted the global severity of RA. The disease is often recognized earlier nowadays, 
and effective treatment often starts before joint destruction has occurred.7,8 In 2010 new 
criteria by ACR and EULAR were released, pertaining to patients with more recent RA.9 
Treatment strategies, aiming at low disease activity assessed by recently developed and 
validated scores, exploiting combinations of antirheumatic drugs, corticosteroids and/or 
biologic therapies, have together resulted in a more effective suppression of  inflammation 
and radiographic progression. To date, RA is a far more manageable disease than decades 
ago, and severe damage to joints and internal organs has become rather rare. RA is to some 
extent comparable to other chronic conditions, such as diabetes, where patients are frequently 
monitored and therapy is adjusted according to laboratory tests, in order to prevent the future 
risk of organ damage.10,11 As a relative novelty in the field of rheumatology, treatment 
decisions may now include decisions about tapering medication when the disease has been 
adequately suppressed, and long-term drug-free remission seems to become a feasible 
reality.12-14 
 
THEAPIES AND TREATMENT MANAGEMENT 
Rheumatologists may use three types of antirheumatic disease modifying drugs (DMARDs): 
1. classical or conventional synthetic (cs) DMARDs, 2.biologic (b) DMARDs and 3. 
corticosteroids. Of the csDMARDs methotrexate (MTX) is most often used, and may be most 
effective. MTX is considered to be the ‘anchor drug’, is well tolerated but rather slow acting 
and may need several months to fully exert its efficacy.15 MTX can be used as monotherapy 
but is claimed to be more effective in combination with other DMARDs. Up to two-third of 
 
 
all RA patients does not achieve a low disease activity state with methotrexate alone and other 
csDMARDs such as sulfasalazine16 and leflunomide17,18 can be chosen as monotherapy or 
added to MTX.19 Also bDMARDs and oral corticosteroids are most effective in combination 
with csDMARDs, preferably MTX. Several studies have shown that a bDMARD plus a 
csDMARD, as well as csDMARDs in combination with oral corticosteroids,20-22 are more 
effective than monotherapy with csDMARDs.23,24  
The third category of DMARDs is glucocorticoids. Glucocorticoids differ from csDMARDs 
in that they usually act very rapidly. Their long term use is disputed because of the fear of 
adverse events, and glucocorticoids are often prescribed only for short periods of time. 
Glucocorticoids can be used orally, but also locally in the form of intra articular injections. 
The main purpose of glucocorticoids is symptom relief by suppression of inflammation, but 
glucocorticoids have also been demonstrated to inhibit radiographic progression, which 
effectively makes them DMARDs.25 
 
Recommendations management RA 
The changes in treatments and treatment approaches during the recent years have resulted in 
new strategies to manage RA. In 2010 collaborating international rheumatologists have 
released a set of recommendations for the management of RA for patients with bDMARDs 
and csDMARDs, to be used in all-day clinical practice.11 In these recommendations the 
values of an early diagnosis, of an early treatment start and of setting treatment goals and 
monitoring them meticulously, have been stipulated. Of note, a shared treatment decision 
between patient and physician, emphasising mutual responsibility for the treatment outcome, 
was considered very important. Also, stepwise algorithms have been developed for the start of 
medication in newly diagnosed patients, with treatment adjustments based on measured 
clinical responses. The procedures also include tapering of medication for patients in 
sustained remission or in a low disease activity state. It is recommended that DMARD 
medication should be intensified or changed if a predefined treatment target was not met 
within a time frame of 3-6 months.10 Such a time frame was not (yet) specified for tapering 
medication in patients with longstanding remission, since patients may flare and therefore 
tapering should be performed cautiously.11 In an attempt to further emphasize the importance 
of meticulous monitoring and guided decisions about treatment intensification, the treat-to-
target (T2T) initiative has formulated recommendations to stimulate rheumatologists to set 
and aim at achieving treatment goals.25 In 2013 the 2010 EULAR recommendations were 
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updated including improved treatment strategies for which scientific proof has become 
available.26 The ultimate goal to achieve in an individual patient with RA is a (long-standing) 
state of remission. To date, a significant proportion of the patients have still not reached this 
target of remission or even a more lenient target of low disease activity.11 This implies that 
the care for RA can still be improved. While improvement of care often has a connotation of 
‘developing better drugs’, in the field of RA a better implementation of existing 
recommendations in daily practice may be similarly effective in achieving this goal.  
 
Treat to target 
As mentioned before, a treat-to-target approach has been formulated to provide guidance for 
the management of RA in clinical practice. It describes definitions for achieving a clinical 
state of remission, and the frequency (every three months in patients with active RA and 
every six months in patients with low disease activity or remission) of patient monitoring 
using validated composite measures.25,27 
Both the EULAR and treat-to-target recommendations have been recognized by experts to be 
associated with better functional and radiographic outcomes.28 Patients agree with these 
recommendations,29 but may experience and interpret symptoms differently than their 
physicians.30-32 Here, a trained nurse could be instrumental in helping patients understand why 
clinicians want to follow a treat-to-target approach.33 
 
Implementation of recommendations in clinical practice 
As mentioned above, better implementation of recommendations in clinical practice is 
important to improve care for RA. In general, increasing numbers of recommendations for 
clinicians have been developed during the past decade. Recommendations seek to improve the 
quality of care, and are thought to have an impact on patient outcomes, and there is a need to 
disseminate and implement them in clinical practice. Implementation of recommendations is 
not easy and not well understood. Strategies of dissemination are important, but previous 
studies have shown that it is not clear which strategy is most appropriate.34,35  
Another factor of importance is related to how physicians interpret the content of 
recommendations: Physicians tend to follow recommendations according to their own 
interpretation, especially if the text of recommendations leaves room for alternative 
interpretations. Another well-known factor interfering with an appropriate implementation is 
the presence of significant comorbidities that may or may not interfere with a correct follow 
 
 
up of recommendations (that often do not specifically include guidance about specific co-
morbidities). Lack of awareness on -and agreement with- therapies are also reasons for not 




Inherent to the treat-to-target strategy is the use of composite scores to evaluate disease 
activity and treatment success. A high score implies high disease activity and a need to 
intensify treatment. During the 1990s these scores have been developed, based on physicians’ 
and patients’ judgement of disease activity, primarily to study the efficacy of treatments in 
clinical trials,39 and later to assess variation of disease activity over time in individual 
patients. The first composite score was the Disease Activity Score (DAS). This measure 
includes the Ritchie Articular Index (RAI) for the assessment of tenderness in 53 joints, the 
number of swollen joints among 44 joints, the erythrocyte sedimentation rate (ESR in mm/hr.) 
and the visual analogue scale (VAS) for patient’s assessment of global health (ranging from 
0-100 with 0=best and 100=worst). All together, these components form the following DAS 
formula: 0.54 * √RAI + 0.0065 * SJC + 0.33 * ln(ESR) + 0.007 * VAS-GH (Patient’s 
assessment of global health, or alternatively, patients’ assessment of global disease activity, 
rated on a 100 mm visual analogue scale, with 0 mm as best and 100 mm as worst possible).40 
The regression coefficients and the mathematical transformations, which are incompletely 
understood and inappropriately valued by many as being too laborious, serve in reality to 
optimize the performance of the DAS in groups of patients and in individuals.  
EULAR has formulated criteria with which patients can be classified as having high 
(DAS>3.7), moderate (DAS: 2.4-3.7) or low disease activity (DAS: 1.6-2.4) or remission 
(DAS<1.6). A clinical improvement is defined when the DAS is 0.6 points lower than at the 
previous visit.41, 42 Later, modifications of the DAS have been developed, such as the DAS28 
including only 28 joint counts for swelling and tenderness.43 Another modification includes 
C-reactive peptide (CRP) instead of ESR. In addition, indices with a far simpler metric have 
been developed to measure disease activity: the Clinical Disease Activity Index (CDAI) and 
the Simplified Disease Activity Index (SDAI).44,45 Theoretically, these simplifications have 
gone at the cost of performance of the indices: At the group level they still work; at the 
individual patient level they may fall short. 
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Nowadays, the DAS (actually often its 28-joint modification with CRP instead of ESR) is one 
of the most used composite scores worldwide. In clinical trials it has been proven that 
adjustment of treatment intensity based on the DAS results in better clinical and radiographic 
outcomes.46-48 However, in terms of implementation, a lot is still to gain: Several studies have 
suggested that DAS-steered therapy is not yet widely applied in clinical practice.49-54 Among 
the multiple alternative explanations, the following two are relevant for the discussion here: 1. 
Physicians may put more value on certain components of the DAS than on the DAS itself, and 
use for instance ESR or swollen joint count rather than DAS to decide about treatment; and 
2.55 Differences between the patient’s and the physician’s perception of the level of disease 




In addition to disease activity, measures for functional disability have been developed in order 
to score how well patients were able to perform daily activities. The most widely used 
measure is the Health Assessment Questionnaire (HAQ). The HAQ consists of 24 questions 
regarding eight distinct categories: dressing, arising, eating, walking, hygiene, reach, grip and 
usual activities.56 The HAQ reflects disability in daily activities. With disability either related 
to actual disease activity or to damage due to previous disease activity, the HAQ can be seen 
as consisting of two components, the reversible and the irreversible HAQ.57 Medication 
changes that suppress actual disease activity may decrease the total HAQ only to the extent 
where sustained damage has a permanent impact on functional ability.57,58 Thus, to avoid 
irreversible disability, disease activity has to be suppressed early, in order to prevent the 
occurrence of joint damage.  
 
Radiologic joint damage 
Earlier treatment initiation and the use of combinations of therapies including oral 
corticosteroids or the newer bDMARDs have resulted in fewer patients developing severe 
joint damage. Ideally, clinical remission (no symptoms of RA activity) is accompanied by 
radiographic remission (absence of joint damage, or no progression from baseline). Joint 
damage can be assessed with several scoring methods.59 For the small joints of hands and feet 
the modified Sharp van der Heijde Score (SHS) is often used, which scores the number and 
severity of erosions and the severity of joint space narrowing in 44 joints of the wrists, hands 
 
 
and feet, resulting in a possible maximum score of 448.60 The SHS is usually applied in 
clinical trials, because it is too comprehensive to apply in individual patients in clinical 
practice, and requires special training. In research, SHS is still considered very important 
because it may reflect the level of disease activity, both in terms of extent and duration. Often, 
(partially) patient-reported outcomes such as DAS and HAQ are tested against the external 
standard of joint damage, quantified by SHS. The Larsen score is most often used to score the 
severity of damage in the large joints (shoulders, elbows, wrists, hips, knees and ankles), and 
has a range from 0 to 5 per joint.61  
 
TREAT TO TARGET: FROM TRIALS TO DAILY PRACTICE 
Many trials have proven the efficacy of targeted treatment with regard to clinical outcomes. 
The TICORA study was the first to demonstrate that targeted treatment aiming at low disease 
activity results in better clinical and radiological outcomes than ‘routine’ interview-based 
care.46 Other trials demonstrating that a treat to target approach may result in remarkable 
clinical and radiological improvement were FINRA-Co,62 CAMERA,63 and the BeSt study.64 
The BeSt study, discussed in some more detail here since data from this study will feature in 
this thesis, has started as a multicentre randomised clinical trial consisting of four treatment 
arms and aimed at effective disease suppression using principles of targeted treatment in 
patients with recently diagnosed active RA. Between 2000 and 2002, 508 patients were 
randomised to: 1) sequential monotherapy of csDMARDs, 2) step-up therapy of csDMARDs, 
3) initial combination therapy of csDMARDs with tapered high-dose prednisone or 4) initial 
combination therapy including infliximab. In addition, intra articular corticosteroid injections 
were allowed at the rheumatologists’ discretion. Every three months, protocolled treatment 
adjustments were made based on the DAS. The HAQ was also completed at each visit. The 
Best study was one of the trials that have shown that DAS-steered treatment may result in 
better long-term clinical outcome, such as functional ability,64 and in less progression of joint 
damage. 
 
METEOR and other databases 
The benefits of DAS-steered therapy have been studied in clinical trials46-48,65,66 including 
optimal protocols, motivated rheumatologists and nurses, and relatively healthy (trial) 
patients. Whether or not treat-to-target is feasible and practiced in common daily clinics, 
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were allowed at the rheumatologists’ discretion. Every three months, protocolled treatment 
adjustments were made based on the DAS. The HAQ was also completed at each visit. The 
Best study was one of the trials that have shown that DAS-steered treatment may result in 
better long-term clinical outcome, such as functional ability,64 and in less progression of joint 
damage. 
 
METEOR and other databases 
The benefits of DAS-steered therapy have been studied in clinical trials46-48,65,66 including 
optimal protocols, motivated rheumatologists and nurses, and relatively healthy (trial) 
patients. Whether or not treat-to-target is feasible and practiced in common daily clinics, 





however, was not well known. The Measurement of Efficacy of Treatment in the ‘Era of 
Outcome’ in Rheumatology (METEOR) database has been developed to help clinicians 
implementing strategies such as treat-to-target in their routine clinical care. The database 
serves as an online software tool for rheumatologists to encourage frequent monitoring, 
subsequent treatment adjustments, and registration of disease activity and physical 
functioning in patients with RA. The METEOR initiative has been started by rheumatologists 
and has been developed for rheumatologists worldwide. Besides composite measures and 
functional ability data, rheumatologists can add information on medication use and other 
patient- and physician- reported outcomes. METEOR can also provide benchmarks to the 
rheumatologist that allows him to compare his performance with that of other 
rheumatologists. This may lead to research comparing data of clinical outcomes in RA care 
within and between countries.67 Apart from METEOR, other international initiatives 
(registers, databases or cohorts) promote T2T in clinical practice and advocate comparing 
clinical outcomes between countries.68,69 Many of these initiatives exploit a rather small 
database and although they may overlap in design and registration, it appears to be difficult to 
combine data for integrated analyses. To improve the quality of research EULAR has 
published a repository of databases in which researchers can collaborate and share 
information on databases, which will be further discussed in this thesis. 
 
International Recommendation Implementation Study (IRIS)  
To study the incorporation of the EULAR and the treat to target recommendations for RA in 
clinical practice and to identify how application of these recommendations by rheumatologists 
could be further enhanced, the International Recommendation Implementation Study (IRIS) 
was started. In the IRIS a survey was established to study whether rheumatologists apply the 
recommendations in clinical practice. A well-recognized pitfall of surveys is that we do not 
know if the outcome of the survey truly reflects daily practice: responses might be influenced 
by ‘desirable’ answers that participants may give.29,50,52,54 
For the IRIS study, rheumatologists worldwide were contacted via their national 
rheumatology societies and asked to participate, and 132 rheumatologists from many 
countries agreed. These were asked to follow an educational program, which included reading 
two scientific papers on treat to target therapy, and watching an educational video. Before the 
educational training they were asked to fill in a questionnaire on their awareness on the 
EULAR and treat to target recommendations. After the educational program, the participating 
 
 
rheumatologists were asked to each include 5-10 newly diagnosed RA patients, which were 
then followed up for one or two years.  
 
OUTLINE OF THIS THESIS 
Main Aims  
 Compare rheumatologists’ agreement with - and their actual performance of - treat-to-
target recommendations in daily clinical practice.  
 Investigating (cultural) differences in perceptions of both the RA-patient and the 
treating physician in rating the global disease activity of the patient  
The main focus of this thesis is on treat-to-target therapy and improving care in RA, in 
particular on rheumatologists’ awareness and the implementation of treat-to-target 
recommendations in daily clinical practice. In Chapter 2 we focused on existing databases in 
the field of rheumatoid arthritis. Here we have described the results of a systematic literature 
review in which we were aiming to provide an overview of the existing European 
(international and national) databases in RA. In four international- and 30 national databases 
we described characteristics, such as the aims, funding, size, year of inception, collection of 
clinical data and participation in the repository of databases. The latter database was set up by 
the EULAR to stimulate collaboration between European researchers. In the context of a DAS 
steered trial (the Best-trial database) we have further investigated the use and the benefits of 
intra articular injections on local inflammation, which includes swollen and tender joints over 
3 months (short term). Over a longer period, intermediate (until 1 year after injection) and 
long term (until 8 years after injection) we investigated the association between intra articular 
injections and systemic clinical outcomes, such as the DAS and HAQ (chapter 3).  
In chapter 4 and 5 we focused on the patient- versus the physician-reported outcomes in RA 
in the METEOR database, since they may have different perceptions of patients’ disease 
activity. We investigated differences in assessments of the patients’ global disease activity by 
patient and physician, and explored which determinants influenced both patients’ and 
physicians’ assessments. We also investigated which determinants were associated with a 
difference (>20mm) in global disease activity score of the patient and the physician.  
In chapter 5 we investigate whether differences between patients’ and physicians’ assessment 
of global disease activity are dependent on the country of residence, as language, patient-
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physician interaction or other cultural differences may affect how patients and physicians 
perceive this subjective outcome.  
In chapter 6 we focussed on whether DAS steered therapy has been applied in clinical 
practice. Questionnaire-based research suggests that rheumatologists apply T2T on a daily 
basis, while on the other hand some observational studies have suggested that DAS steered 
therapy is infrequently practiced. Therefore we have investigated whether - and if yes: to what 
extent - DAS steered therapy has been applied in a clinical practice database (METEOR). The 
association between level of DAS and treatment adjustments was compared in various DAS-
classification groups.  
In chapter 7 we showed the first results of the IRIS study. This study compared 
rheumatologists’ willingness to use a T2T approach, as based on the results of a 
questionnaire, with subsequent data from the METEOR database showing how T2T is 
implemented by these rheumatologists in daily practice. Since the questionnaire was followed 
up by an educational program on the EULAR and T2T recommendations, we will be able to 
give an impression on whether such an educational program is useful in the process of 
implementing recommendations in clinical practice.  
In chapter 8 we summarized and discussed the results of the studies reported in the thesis. 
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To evaluate current (inter)national registers and observational cohorts in Europe, and to 
compare inclusion criteria, aims, collected data and participation in the EULAR repository. 
  
Methods 
We performed a systematic search strategy in six literature databases. Publications reporting 
European (inter)national prospective registers/cohorts including >200 RA patients with at 
least half a year of follow-up were selected.  
 
Results 
In total, 417 articles and abstracts were included, which described 4 international databases 
and 39 national databases/cohorts. International databases were of roughly similar design, 
frequency of data collection and selection criteria and are mostly initiated to monitor and 
compare clinical patient care among countries. National databases/cohorts vary in aims and 




Our findings may indicate that among researchers there is little awareness of 
recommendations to set up registers or cohorts and of the existence of the database 






The development of treatment care in rheumatoid arthritis (RA) is usually studied in 
randomized clinical trials (RCTs). However, it is well known that patients included in clinical 
trials often differ from patients in standard care due to specific inclusion criteria.1,2 Patients in 
RCTs in general have higher disease activity and less or no co-morbidities compared to 
patients in cohorts.3  
More valuable ‘daily practice’-based information may be found in large representative long-
term registries that have been established to monitor patients specifically in clinical practice.4 
Already some reviews compared characteristics of various registries to investigate differences 
between treatment results in clinical practice and RCTs.5,6  
It appears that despite the availability of international recommendations on management of 
RA and similar access to the same drug therapies, important differences in outcomes remain. 
This may be due to variations in defining outcomes, or differences in local culture or 
variability in the use of biological agents (e.g. invoked by reimbursement policies or access to 
health care). In addition, the inclusion criteria, design and purpose of such registries may 
greatly influence the results of a database analysis. To improve collaboration between 
European rheumatologists, the European League Against Rheumatism (EULAR) has recently 
started a repository of databases, which can be used as a platform for researchers to start 
collaborative projects.  
In this article we aim to give a complete overview of the existing large registers and cohorts 
in Europe (international, national, regional and local), to inform on participation of these 
databases in the EULAR repository and to provide details on inclusion criteria, aim of the 
registry and its data collection.  
 
METHODS 
Retrieval of possibly relevant references 
A literature search was performed according to the PRISMA statement7,8 for cohorts, 
registries and databases on of three types: international (more than one European country 
captured), national (captured centers in all parts of the country), regional (captured centers in 
more than one city in the same region) and local (captured one or more centers in a city). We 
searched in six databases; PubMed, Embassy, Web of Science (WOS), Academic Search 
Premier, Wiley-Blackwell and LWW. In collaboration with a trained librarian (JL), an 
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extensive search strategy was formulated (Attachment I). Search strategies for the other 
databases were formulated similarly but adjusted to the specific database. References were 
stored and deduplicated in a Reference Manager database. While recognizing the existence of 
numerous RA registries, we identified publications that were best served for our aims.  
 
Selection of references 
Criteria to include a reference or an article were:  
1) The disease studied was at least RA 
2) The database/study was prospective and longitudinal  
3) The study was initiated in Europe  
4) The study included more than 200 study participants  
5) The study had at least half a year of follow-up.  
Articles or abstracts were excluded if they described: 
Cohorts/databases that also studied patients with non-rheumatologic diseases (such as studies 
based on hospital discharge registers, health service registers, and population based cohorts)  
Case control studies.  
The selection procedure consisted of 2 phases: 
Two independent investigators (EG and RK) screened the references by title or abstract for 
selection. Differences were resolved by agreement. After this, the full text of the remaining 
articles and abstracts was read and reviewed extensively by one investigator (EG).  
Additionally, a questionnaire was sent to 47 national societies of rheumatology connected to 
the EULAR asking for the presence and features of any RA or arthritis databases in their 
country. Both the questionnaire and the literature search were used to select the databases and 
cohorts for our study.  
 
RESULTS 









































Figure 1. PRISMA Flow chart inclusion.  
 
 
Records identified through database 
searching  
(n = 7165) 
Additional records identified 
through the questionnaire  
(n = 5) 
Records after duplicates removed  
(n = 5078) 
Records screened (n = 5078): 
Pubmed, (n = 2266) 
Embase, (n = 1787) 
WOS, (n = 1859) 
Academic Search Premier, (n = 622) 
Wiley-Blackwell, (n = 90) 
LWW, (n = 261) 
Science direct, (n = 280) 
 
Records excluded  
(n = 4155) 
Full-text articles and 
abstracts assessed for 
eligibility  
(n = 923) 
Full-text articles and 
abstracts excluded 
(n = 505) 
Studies included in 
qualitative synthesis  
(n = 418) 
418 articles/abstracts divided over: 
International Databases, (n = 4) 
National databases, (n = 31) 
National Arthroplasty registers, (n=8) 
Regional databases, (n=16) 
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4155 references were excluded after screening of the titles and abstracts, which left us with 
923 references. After reading the full text of the publications, another 506 references were 
excluded, resulting in a final set of 417 articles and abstracts for inclusion. The response rate 
of the questionnaire was 32/47 (68%) which provided us with 5 additional databases, of which 
no publications were found identified in the literature search. We identified combining both 
strategies 4 international databases, 39 national databases (7 of which were left out when they 
proved to be arthroplasty registers), 16 regional databases and 25 local databases. For some 
databases, more than one publication was available to describe all features. Approximately 
half of the databases were described once (n=33) or twice (n=12) but 5 databases were 
described in more than 20 publications (table 1).  
The characteristics of the 4 international and the 32 national registers were further described 
and summarized in the tables, with focus on the following features: funding, aims, number of 
patients, year of inception, clinical evaluation of the physician, patient reported outcomes, 
laboratory information, radiographic imaging, drug treatment, frequency of data collection, 
selection criteria for enrolment into the registry, control groups, rheumatic diseases captured, 
connection to the EULAR repository of databases and the number of publications. Not all 




Table 2 describes the four international databases that we have found: METEOR 
(Measurement of Efficacy of Treatment in the Era of Outcome in Rheumatology), GoTreatIt, 
Quest-RA (Quantitative Patient Questionnaires in Standard Monitoring of Patients with 
Rheumatoid Arthritis) and Cererra (the European Collaborative Registries for the Evaluation 
of Rituximab in Rheumatoid Arthritis).4,9,10  
All databases are practice-based registers, collecting clinical information on RA patients. The 
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RA and response to treatment.  
 
 









Databases not described in 
publications, n* 
3 0 1 5 
databases described in: 









2 publications, n 8 1 3 12 
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5 publications, n   2 0 1 3 
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14 publications, n 1 0 0 1 
16 publications, n 0 1 0 1 
17 publications, n 0 0 1 1 
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They are based on and aim to promote using composite scores as tools to monitor disease 
activity.10 Quest-RA is a monitoring program for standard care in RA.4 Cererra is a drug-
safety register with a fixed (every 0, 3, 6, 9 and 12 month’s patients are seen) monitoring 
protocol the efficacy of rituximab in RA.9 METEOR, QUEST-RA and GoTreatIt follow 
patients without fixed monitoring time points. The largest database is METEOR with more 
than 17.000 patients registered including at least one entry of disease activity; the database 
covering the highest number of countries (N=20) is QUEST-RA. METEOR, Quest-RA and  
Cererra are funded by pharmaceutical industry and GoTreatIt by the government.
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Distribution: Attachment II; table 1 shows the national databases and cohorts in Europe. 16 
European countries have nationally based databases or cohorts. Most of them were found in 
France (n=4), Spain (n=4) and the United Kingdom (n=4). However, the largest registers 
were found in the United Kingdom, Germany and Denmark. 
Size/number of publications: The largest registers with more than 10.000 patients are the 
British Society for Rheumatology Rheumatoid Arthritis Register (BSRBR) (N≈20.000, 44 
publications), the German Collaborative Arthritis Centers (N≈15-17,000, 26 publications), 
the Danish Registry for Biologic Therapies in Rheumatology (DANBIO) (N≈10.000, 14 
publications) and the German biologics register (RABBIT) (N≈12.303, 20 publications). 
DANBIO, BSRBR and Rabbit are aiming at efficacy of the biologic drugs and all include 
early and established RA patients, while the German Collaborative Arthritis Centers is 
established for epidemiologic purposes and includes all RA patients, without restriction of 
drug use.11-14 Eleven databases are currently closed, 15 are ongoing and for six databases the 
size was not reported (Attachment II; table 1). 
Year of inception: The inception of the cohorts and registers varies between 1986 and 2011. 
The largest registers were not all the oldest registers. The oldest cohort is the Early 
Rheumatoid Arthritis study (ERAS) which started in the United Kingdom, in 1986. Also 
long running are the Norfolk Arthritis Register (NOAR, 1989), the national database of the 
German Collaborative Arthritis Centers (since 1993), the Early Swedish Rheumatoid 
Arthritis Register (RAMONA) (since 1995) and the Swiss Clinical Quality Management 
program for RA (SCQM-RA) (since 1997). These older databases differed in aims and 
inclusion criteria. ERAS and RAMONA primarily aimed at monitoring clinical disease 
activity and included only early RA patients.15,16 NOAR, SCQM-RA and the German 
Collaborative Arthritis Center have different purposes (predictive, monitoring and 
epidemiologic respectively) but similar inclusion criteria.13,17,18  
Diseases captured: 23 databases described both early and established RA, 6 only early RA 
and 2 only established RA. Approximately half of the databases are covering more 
rheumatologic diseases besides RA such as Spondyloarthritis or Psoriatic Arthritis 




Selection criteria for enrolment into the registry: selection criteria vary with the main aims 
of the registry. We divided the registries in two sections based on aims as described in the 
publications: Fifteen registries have as primary aim to investigate efficacy and safety of 
biologic (or other) treatments. Inclusion criteria for these registers were for 14/15 both early 
and established RA. Most (11/15) of the efficacy registers were biologic registers. 8 of the 
registers aim at monitoring disease activity and benchmarking for clinical practice purposes. 
Inclusion criteria were for 4/6 both early an established RA patients, for 1 register 
established and for 3 registers early RA patients. Half of the latter register types are not 
connected to the EULAR repository of databases. Four registries serve epidemiological 
purposes, studying the prediction of outcome and aetiology. Inclusion criteria varied from 
established RA (n=1) to both established and early RA (n=3). Four registers aimed at 
monitoring one (biologic) drug in particular (Autoimmunity and Rituximab in RA cohort, 
MAbThera registry in RA, Orencia and RA study, medico-economic evaluation of 
infliximab study.19-21 
Therapies: DMARDs and/or biologic agents are registered in 31/32 databases.  
Frequency of data collection: In 11 of the databases, data collection is performed on a 
continuous basis, each time the patient visits the physician and not only at predefined time 
points. For the fixed protocols, seven databases include data collected every 3 months and 7 
databases collected data every 6 months (Attachment II; table 1). 
Physician/clinical evaluation: 31 registries collect Disease Activity Score (DAS) and/or 
DAS components, 19 of the registers use the DAS28 score. 4 registers report CDAI and 
SDAI and four registries also report morning stiffness.11,14,16,19, 22-24 
Patient reported outcomes (PROs): 25 registries report results of the Health Assessment 
Questionnaire (HAQ), or alternatives/derivatives of the HAQ such as the Functional Status 
Questionnaire Hannover (FFbH). Results of the short-form-36 health survey questionnaires 
(SF-36) was reported in the BSRBR, the Early Rheumatoid Arthritis Network cohort 
(ERAN), the Gruppo Italiano Artrite Reumatoide Aggressiva (GIARA)-registry, the 
Norwegian disease-modifying antirheumatic drug register (NOR-DMARD) registry, study 
for the medico-economic evaluation of infliximab (EMER study), NOAR and the rheumatic 
diseases Portuguese register (Reumapt).12,17,20,25-28 The RADAI (self-administered 
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rheumatoid arthritis disease activity index) was reported in the Swiss SCQM-RA and in the 
Belgian MIRA register.18,21 
Additional (Labs/radiographies/imaging): All registries report CRP or ESR as acute phase 
reactants; radiographic information was collected in 50% of the registers, however for 
biological databases radiological measures (such as x-rays) were not always done or 
reported (Attachment II; table 1).  
Funding: 16 of the databases are funded by pharmaceutical industries; also government, 
charity, health care, private sources and rheumatologic associations are funding registers. 
Most (11/14) of the biologic registers were funded by pharmaceutical companies 
(Attachment II: table 1).  
Connection to EULAR: 16 of the 32 databases were connected to the EULAR repository of 
databases.11-15,17-19,22,27-33 
Main differences: databases were distributed over 16 national countries, which shows that 
the population is various. The smallest database was Iceland’s biologics register containing 
214 subjects and the largest was BSRBR, with approximately 20.000 subjects.12 A wide 
range between years of inception (24 years between the youngest (Biologic register Austria) 
and the oldest (ERAS) cohort) shows that there is a continuous need, and apparently renewal 
of funds, to start these registries and databases. Furthermore there are differences in 
inclusion criteria (only RA or also other diseases, only early RA, or also established RA, 
only one biologic therapy or all treatments), and in timing and regulation of data collection.  
Main similarities: almost all databases collected similar drug information and clinical 
outcomes (patient reported outcomes and physicians evaluation). 
 
DISCUSSION 
In this systematic review we described four international and 32 national RA databases and 
cohorts of rheumatoid arthritis patients. The international initiatives have roughly similar 
aims, unrestricted inclusion criteria and continuous data collection, enabling comparisons of 
patients in daily practice between countries. The included patients have various degrees of 
disease severity, and are treated with a wide range of synthetic and biologic DMARDs.4,9,10 
It is not clear which percentages of eligible patients are included, and by what selection 
criteria this is determined. Thus, the included patients appear to represent patients from 
 
 
normal daily practice, but may still present a selected population. Having been initiated 
relatively recently (between 2004 and 2008), these databases are mostly still collecting data 
and have not led to many publications, in comparison to some of the national databases .All 
four international initiatives are funded by pharmaceutical industry or the government and 
they are not connected to the EULAR repository of databases. 
The national RA databases were set up between 1986 and 2010; approximately half of them 
are still ongoing.11-40 16 of these national databases were mentioned in the EULAR 
repository for databases. Although there are differences in inclusion criteria, aim, frequency 
of data collection and distribution among countries in Europe, the national databases 
generally collect similar patient reported outcomes, physician clinical evaluation and 
medication. This may stem from government requirements to monitor safety of recently 
introduced therapies, which may also explain involvement of sponsors from the 
pharmaceutical industry. Four databases appear to have been initiated to monitor patients 
treated with one (biologic) drug in particular.19-21 The similarities also may indicate that 
there is not so much a need for new data, but a desire to ‘own’ one’s own data to do research 
and write scientific papers. However, research on individual databases may be hampered by 
small numbers, but the (small) differences among the registries make the data of various 
databases difficult to compare or pool with others. This itself may be a reason to start yet 
again a new (large and/or international) database or registry. Curtis et al. and Zink et al. 
focused on biological registers while comparing characteristics of international databases. 
They found in concordance to our results that there is heterogeneity among databases, which 
Zink et al. suggest may lead to further analyses and new information.5, 6 
Mostly the oldest and largest national databases are connected to the EULAR repository of 
databases.11-18 It appears not all researchers are aware of or follow recommendations to set 
up registries or cohorts, nor aware of the EULAR network and database repository that aims 
to support collaboration between database researchers.  Since databases and registries mostly 
have been initiated to provide information that may be missed in RCTs, it is relevant to 
identify if the results of these initiatives have been published in medical journals. Without 
publication, the effort of building the database may not be matched by the output of little 
information to few direct users. We found that in particular results from older and larger 
databases have been published. Some registers had few or no publications, which might be 
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due to difficulties in retrieving information from the registry, possibly due to the size and set 
up of the registry, incomplete data collection or poor IT support. These problems could be 
prevented when researchers connect their registers to the EULAR repository of databases. It 
has to be kept in mind that despite resembling daily practice, intentional or unintentional 
selection of patients whose data will enter the database may compromise generalizability of 
the database results.  
In conclusion, through a systematic literature search and an additional inventory by 
questionnaire we found four international RA databases with similar inclusion criteria and 
content and frequency of data collection, and 32 national RA databases or registries, which 
differ substantially. Half of these databases, the oldest and largest with most publications, are 
connected to the EULAR repository of databases. It may be worthwhile for the others to join 
initiatives such as the EULAR repository for databases for collaboration between cohorts, to 
decrease differences in database structure and content and to improve quality of research and 
output. Since half of the databases is not joining the EULAR repository of databases, our 
results provide a more complete overview of the current present databases than the EULAR 
repository of databases. This overview is useful for researchers that want to start 
collaborations with researchers of databases that answer their research questions. Also 
researchers of existing databases can collaborate and compare data. Via this overview they  
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differ substantially. Half of these databases, the oldest and largest with most publications, are 
connected to the EULAR repository of databases. It may be worthwhile for the others to join 
initiatives such as the EULAR repository for databases for collaboration between cohorts, to 
decrease differences in database structure and content and to improve quality of research and 
output. Since half of the databases is not joining the EULAR repository of databases, our 
results provide a more complete overview of the current present databases than the EULAR 
repository of databases. This overview is useful for researchers that want to start 
collaborations with researchers of databases that answer their research questions. Also 
researchers of existing databases can collaborate and compare data. Via this overview they  
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Attachment I. Full search strategy for PubMed.  
("Arthritis, Rheumatoid"[mesh] OR "Rheumatoid Arthritis"[all fields] OR ra[ti] OR 
"Rheumatoid Nodule"[all fields] OR "Rheumatoid Vasculitis"[all fields]) AND ("Databases, 
Factual"[Mesh] OR "database"[all fields] OR "databases"[all fields] OR "Registries"[Mesh] 
OR "registry"[all fields] OR "registries"[all fields] OR "register"[all fields] OR 
"internet"[Mesh] OR "internet"[all fields] OR "software"[mesh] OR "software"[all fields] OR 
"Cohort Studies"[Mesh] OR "cohort"[tiab])  AND (“international”[tiab] OR “national”[tiab] 
OR "Europe"[Mesh] OR "europe"[tiab] OR "european"[tiab] OR "Andorra"[tiab] OR 
"Andorran"[tiab] OR "Austria"[tiab] OR "Austrian"[tiab] OR "Belgium"[tiab] OR 
"Belgian"[tiab] OR "Albania"[tiab] OR "Albanian"[tiab] OR "Estonia"[tiab] OR 
"Estonian"[tiab] OR "Latvia"[tiab] OR "Latvian"[tiab] OR "Lithuania"[tiab] OR 
"Lithuanian"[tiab] OR "Baltic"[tiab] OR "Bosnia-Herzegovina"[tiab] OR "Bosnian"[tiab] OR 
"herzegovinian"[tiab] OR "Bulgaria"[tiab] OR "Bulgarian"[tiab] OR "Croatia"[tiab] OR 
"Croatian"[tiab] OR "Czech"[tiab] OR "Hungary"[tiab] OR "Hungarian"[tiab] OR 
"Macedonia"[tiab] OR "Macedonian"[tiab] OR "Moldova"[tiab] OR "Moldovian"[tiab] OR 
"Montenegro"[tiab] OR "Montenegran"[tiab] OR "Poland"[tiab] OR "Polish"[tiab] OR 
"Republic of Belarus"[tiab] OR "belarian"[tiab] OR "Romania"[tiab] OR "Romanian"[tiab] 
OR "Russia"[tiab] OR "Russian"[tiab] OR "Serbia"[tiab] OR "Serbian"[tiab] OR 
"Slovakia"[tiab] OR "Slovakian"[tiab] OR "Slovenia"[tiab] OR "Slovenian"[tiab] OR 
"Ukraine"[tiab] OR "Ukrainian"[tiab] OR "Yugoslavia"[tiab] OR "Yugoslavian"[tiab] OR 
"Finland"[tiab] OR "Finnish"[tiab] OR "France"[tiab] OR "French"[tiab] OR "Germany"[tiab] 
OR "German"[tiab] OR "Gibraltar"[tiab] OR "Gibraltarian"[tiab] OR "Great Britain"[tiab] 
OR "British"[tiab] OR "United Kingdom"[tiab] OR "Greece"[tiab] OR "Greek"[tiab] OR 
"Iceland"[tiab] OR "Icelandic"[tiab] OR "Ireland"[tiab] OR "Irish"[tiab] OR "Italy"[tiab] OR 
"Italian"[tiab] OR "Liechtenstein"[tiab] OR "Luxembourg"[tiab] OR "Luxembourgian"[tiab] 
OR "Monaco"[tiab] OR "Monegasque"[tiab] OR "Netherlands"[tiab] OR "dutch"[tiab] OR 
"Portugal"[tiab] OR "Portuguese"[tiab]
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To investigate the association between intra-articular (IA) large joint corticosteroid injections 
and clinical outcomes in patients with recent onset rheumatoid arthritis (RA). 
 
Methods 
We compared pain (visual analogue scale (VAS)), the Disease Activity Score (44 joints) 
(DAS) and swollen and tender joint counts before and after IA injection. Using linear mixed 
models (LMM) the DAS and the Health Assessment Questionnaire (HAQ) score over time 
were compared in IA injected versus non-injected patients.  
 
Results 
In year 1, 93 joints were injected in 44 patients treated with initial methotrexate 
monotherapy, and 16 in patients treated with initial combination therapy (p<0.01). Three 
months later, swelling and tenderness were resolved in 50-58% of the injected joints but 
within 12 months after the injection, swelling recurred in 14% and tenderness in 41% of the 
injected joints. Mean (SD) DAS decreased from 4.0 (1.4) before to 3.2 (1.2) 3 months after 
injection (p<0.01) and VAS for pain from 49 (26) to 40 (27) (p<0.01). LMM showed a higher 
DAS and HAQ in patients injected in year 0-1 compared to those not injected, but no 
difference in subsequent years, and similar treatment adjustments. Eight year radiographs 
showed similar damage in injected joints (17%) and non-injected joints (14%). 
 
Conclusion  
IA corticosteroid injections are associated with symptom relief, sometimes only temporarily, 
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Inflammation of joints in rheumatoid arthritis (RA) causes pain and loss of physical function 
and eventually may result in joint destruction. Current treatment consist of disease-modifying 
anti rheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), biological 
agents and oral corticosteroids.1 In addition, intra articular (IA) corticosteroid injections are 
given, mostly in the large joints, as local therapy to reduce pain and swelling.2-6 In daily 
practice short term effect varies per patient due to accuracy and needle placement, type of 
corticosteroid, misdiagnosis of inflammation.5,7,8 Long term, IA-injections in combination 
with DMARDs are suggested to have a positive effect on inflammation in RA. 9   
In the BeSt study, which compares 4 different treatment strategies aimed at a Disease 
Activity Score (DAS) =<2.4 in patients with recent onset RA, we investigated the association 
of IA-injections in the large joints with disease activity and functional ability in the first year 
and over 8 years of treatment including number of treatment adjustments and radiological 
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elsewhere.10 In all four groups, IA injections were allowed at the rheumatologists’ discretion. 
Intra muscular injections were not allowed. For the current analysis patients who received IA 
injections in the large joints during the first year, and patients who did not were compared. 
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(between t=2 years and t=8 years) outcomes were measured every three months using the 
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100=worst) for pain, the DAS, with local swelling (based on a 44 joint count) and tenderness 
(measured in 51 joints with the Ritchie Articular Index), and functional ability (Health 
Assessment Questionnaire HAQ).11 Radiological damage defined as a Larsen score >=1 and 
the number of treatment adjustments (made when three monthly DAS as measured by trained 
nurses was >=2.4) were used as secondary outcome measure in the analyses. 
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Descriptive analyses using X2-test for categorical data and analysis of variance (ANOVA) or 
Kruskal-Wallis test for continuous data were performed, depending on normal distribution of 
the tested variable. Short term associations of IA injections were tested with a paired T-test. 
Aiming to correct for patient selection resulting in IA injected patients being more likely 
have more active RA, we used propensity scoring.12 The propensity model included the 
following covariates: gender, age at inclusion, body mass index (BMI), rheumatoid factor 
(RF) status; anti-cyclic citrullinated peptide (ACPA) status; baseline total Sharp van der 
Heijde Score (SHS), DAS, HAQ, treatment strategy, swollen joint count, tender joint count, 
patient’s assessments of global disease activity and pain on a visual analogue scale (VAS) 
and doctor’s VAS for disease activity. The propensity score showed moderate to good 
discrimination, the area under the receiver operating characteristic (ROC) curvewas 0.73 
(95% confidence interval 0.67-0.80).  HAQ and DAS over time in injected and non-injected 
patients, adjusted for propensity score and follow-up time, were compared using a linear 
mixed-effects model (LMM) analysis. Logistic regression was performed to analyze the 
association of IA injections on radiological damage after 8 years, corrected for the propensity 
score. Univariate linear model building was used to measure the association between 
injections (yes/no) on the number of high DAS44 steered treatment adjustments within the 
treatment arms (post-hoc test). Software program SPSS version 17.0 was used for the 
analyses; p-values were reported two-sided and p-values smaller than 0.05 were considered 
statistically significant.  
 
RESULTS 
Of the 508 patients, 60 patients (12%) were injected in one or more large joints (n=93) during 
the first year of treatment, 42 (60%) of whom were women. At baseline, patients who would 
receive IA injections had a significantly higher mean DAS, HAQ, number of swollen and 
tender joints than the non-injected patients (table 1).  
Of the injected joints, 32 (34%) were knees, 29 (31%) shoulders, 19 (20%) wrists, 7 (8%) 
ankles, 5 (5%) elbows and 1 (1%) hip. Depending on preference in the participating hospitals, 
47 (52%) joints were injected with triamcinolonacetonide (Kenacort), 12 with 




Table 1. Baseline characteristics in injected patients versus the rest of the patients. 
n=number, SD=standard deviation, IQR = interquartile range, BMI= body mass index, ACPA = 
anti−citrullinated protein antibody, RF = rheumatoid factor, DAS44= Disease Activity Score in 44 
joints, HAQ= Health Assessment Questionnaire, VAS = visual analogue scale 
 
 
Recurrence of symptoms was similar after these types of injections (data not shown). 
Significantly (p<0.01) more injected patients, n=44, had been allocated to initial 
monotherapy in strategy arms 1 and 2 than to the initial combination therapy in strategy arms 
3 and 4 (n=16) (Figure1).  
 IA-injection during 
first year, 
 n=60 
No IA injection 





Women, n (%) 42 (60) 301 (67) 0.66 
Age (years), mean (SD) 55 (14) 54 (13) 0.64 
BMI, mean (SD) 26 (4) 26 (4) 0.37 
Symptom duration (wks) median (IQR) 21 (12 to 57) 24 (14 to 53) 0.46 
ACPA positive, n (%) 34 (57) 266 (62) 0.15 
RF positive, n(%) 39 (65) 290 (65) 0.97 
Smoking, n (%) 35 (58) 292 (66) 0.26 
Alcohol, n (%) 33 (55) 229 (52) 0.64 
DAS44, mean (SD) 4.7 (0.8) 4.4 (0.9) <0.01 
HAQ, mean (SD) 1.6 (0.6) 1.4 (0.7) <0.01 
VAS pain, mean (SD) 58 (25) 53 (21) 0.10 
VAS disease activity (patient) mean (SD) 65 (21) 59 (22) 0.07 
VAS morning stiffness, mean (SD) 62 (23) 59 (24) 0.48 
VAS general well-being, mean (SD)  55 (19) 52 (20) 0.19 
Swollen joint count large joints, mean (SD) 3.7 (1.9) 3.0 (1.9) <0.01 
Tender joint count large joints, mean (SD) 5.4 (2.6) 4.7 (2.7) 0.05 
VAS  disease activity (physician), mean (SD) 62 (17) 56 (18) 0.06 
Treatment strategy, n (%) 
Sequential monotherapy  
Step-up combination therapy  
Initial combination with prednisone 
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Figure 1. Percentage of injected joints in patients per treatment group. 
 
 
Pre-injection, local joint swelling as assessed by the study nurses was present in 41 (46%) of 
injected joints, local tenderness in 56 (63%), and both local tenderness and joint swelling in 
31 (36%) of the injected joints. 24 joints were deemed by the research nurse to be neither 
swollen nor tender. Three months after the first injection, 27(50%) of the swollen joints were 
no longer swollen and 23 (58%) of the tender joints were no longer tender. Mean (SD) DAS 
before and 3 months after IA injection was 4.0 (1.4) and 3.2 (1.2), respectively (p<0.01) and 
VAS for pain before and 3 months after IA injection was 49 (26) and 40 (27), respectively 
(p<0.01). 
Within 12 months after the injection, swelling recurred in 3/12 (14%) of the resolved swollen 
joints after injection and tenderness recurred in 11/27 (41%) of the resolved tender joints 
after injection.  
Seventeen joints were injected twice in the first year of treatment. Three months after the 
second injection, 3/9 of the tender joints were no longer tender, and 2/6 of the swollen joints 
were no longer swollen. Five joints were injected a third time, resulting in non-tenderness 
three months later in 1/5. In 10 (38%) of the injected patients that reached a DAS44 =<2.4 in 
the first year, no systemic treatment adjustment occurred. During year 0-1, IA injected 
patients had a higher DAS44 than non-injected patients, mean (95% CI) 3.66 (3.48 to 3.84) 
versus 2.80 (2.73 to 2.87) and higher HAQ 0.96 (0.84 to 1.08) versus 0.78 (0.74 to 0.82) 
 
 
(p<0.01), after propensity scoring. However these were less than the minimal clinically 
significant difference.13, 14 Between t=1 year and t=2 years, and between t=2 years and t=8 
years, there were no significant differences in DAS and HAQ over time between injected and 






























Figure 2. Predicted mean HAQ (Health Assessment Questionnaire and mean DAS44 (Disease 
activity score in 44 joints) based on a linear mixed models analysis in injected patients versus non 
injected patients during the eight years of follow-up. 
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Figure 2. Predicted mean HAQ (Health Assessment Questionnaire and mean DAS44 (Disease 
activity score in 44 joints) based on a linear mixed models analysis in injected patients versus non 
injected patients during the eight years of follow-up. 





From baseline until year 8, the number of treatment steps taken in the four strategy groups 
was similar in the injected patients and the non-injected patients (table 2). 
Radiographs, assessed at t=8 years in the BeSt protocol, were available for 51% (n=46) of the 
injected joints, and 53% (n=3179) of the non-injected joints, in 28 (47%) injected and 262 
(58%) non-injected patients.  
Radiological damage was present in 17% (n=8) of the radiographs of injected joints, and in 
14% (n=453) of the radiographs of non-injected joints. Since there were no baseline 
radiographs, progression could not be scored. On patient level, no significant (p=0.67) 
association between IA injection and damage was present, adjusted for propensity score (OR: 
0.82, 95% CI 0.33 to 2.03). 
 
 
Table 2. Univariate linear model showing number of treatment steps after 8 years for   injected versus 





In recent onset RA patients, randomized in the BeSt study to start treatment with either 
methotrexate mono-or with combination therapy, intra-articular corticosteroid injections were 
allowed at the discretion of the rheumatologists. Joint swelling and tenderness outcomes were 
assessed at 3-monthly intervals by trained nurses who calculated the Disease Activity Score 
(DAS). The 12% injected patients improved in clinical outcomes (VAS pain, DAS, HAQ) 
 Injected in the first year (yes/no) 
 Yes No p-value 
Sequential monotherapy, 
mean (95% CI) 
3.7 
(2.02 to 4.43) 
2.3 
(1.38 to 3.35) 
0.10 
Step-up combination therapy,  
mean (95% CI) 
3.5 
(1.99 to 5.08) 
2.4 
(1.40 to 3.46) 
0.12 
Initial combination with prednisone, mean 
(95% CI) 
1.0 
(-0.99 to 2.98) 
1.7 
(1.10 to 2.30) 
0.49 
Initial combination with infliximab, 
mean (95% CI) 
1.0 
(-0.50 to 2,47) 
2.2 




after three months and a year after injection. Local swelling resolved in 50% and tenderness 
in 58% of injected joints, but within 12 months recurred in 14% of previously swollen and 
41% of previously tender injected joints.  Injected patients had a higher baseline DAS and 
HAQ, and were more often randomized to the initial monotherapy arms of the BeSt trial. 
These arms overall required more treatment adjustments than the initial combination therapy 
arms in year 1. After propensity scoring to correct for differences between the injected and 
non-injected patients using, we found that in the years following the injections there were no 
significant differences in DAS and HAQ over time between injected and non-injected 
patients. Also number of three-monthly treatment adjustments that were required if DAS was 
>=2.4 were similar between injected and non-injected patients within the treatment strategies 
over 8 years. In the linear mixed model analysis, IA injections were not associated with DAS 
and HAQ reduction in the subsequent years after IA injection.  
Our data suggest that IA injections are associated with short term symptom relief in patients 
with early RA. Assuming that injected patients had more active disease than non-injected 
patients, IA injections in year 1 also seem to be associated with suppression of disease 
activity in the longer term, as injected and non-injected patients had over time similar disease 
activity and functional ability, required similar number of systemic treatment adjustments and 
had similar prevalent local joint damage at t=8 years.  
One may argue that an early success rate of 50% to 58% of a local anti-inflammatory 
treatment is disappointing, in particular when symptoms sometimes rapidly return. Although 
previously described15 we found no association between recurrence of symptoms and type of 
corticosteroid used for the injections. However, incorrect placement of some injections, 
which in our study were almost all given blind, may have occurred. Previous studies have 
shown that ‘blind’ injections are misplaced in 18-63% of cases.16, 17 However, some reports 
described that incorrect located injection still results in local symptom relief.18 Furthermore, 
the treating rheumatologists may have injected joints that were most severely or persistently 
inflamed and were less likely to show a complete and lasting immediate response. Since our 
study relies on joint assessments from study nurses (unaware of treatment strategy) rather 
than those of treating rheumatologists, some discrepancies may be explained. On the other 
hand, some joints injected might not have been inflamed with rheumatoid arthritis. The fact 
that some were injected more than once and never responded might also indicate non-
inflammatory osteoarthritis or cuff lesions.  
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The BeSt protocol required radiographs to be taken of all large joints after 8 years, but was 
found only available in 51% of the injected joints (and 53% of non-injected joints). We 
cannot verify if damage was already present at baseline, which might have triggered the 
injections, nor can we evaluate whether damage has developed or progressed over time in 
relation to the injections. The fact that damage was found in 17% of available injected joints 
and in 14% of available non-injected joints suggests that injected joints do not have more 
damage than non-injected joints, and that the injections at least were not detrimental to the 
integrity of the joints. A further limitation of the study was the incomplete data on intra 
articular injections in the years 2-8. We estimate that this occurred less often than in year 1, 
as during treat-to-target therapy, in the majority of patients disease activity was well 
suppressed,19, 20 and few joints in year 1 were repeatedly injected, but we verify this for lack 
of details. The small number of injections the second and the third time and the available data 
of swollen and tender joints 1 year after injection may be a limitation in itself.  
In conclusion, rheumatologists injected large joints with corticosteroids predominantly in 
recent onset RA patients with high disease activity, resulting in an adequate local response in 
about 50% of the injected joints. Joint swelling recurred within 1 year in only 14% which 
suggests that in early RA, joint injections with corticosteroid are associated with symptom 
relief and adequate suppression of local inflammation. Overall DAS and HAQ were reduced 
and over following years similar to DAS and HAQ in non-injected patients, and the numbers 
of three-monthly systemic treatment adjustments in this treat to target study were similar. 
Finally, radiographs of injected versus non-injected joints at 8 years suggests that there is 
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To compare the patient’s (PtGDA) and physician’s (PhGDA) assessment of global disease 
activity and to identify factors that might influence these differences, as well as factors that 
may influence the patients and the physicians score separately. 
 
Methods 
Anonymous data were used from 2.117 Dutch patients included in the METEOR database. 
PtGDA and PhGDA were scored independently on a 100mm visual analogue scale (VAS) 
with 0 and 100 as extremes. The agreement, Intraclass correlation coefficients (ICC), was 
calculated and a Bland Altman plot was created to visualize the differences between PtGDA 
and PhGDA. Linear Mixed Model analysis was used to model PtGDA and PhGDA. Logistic 
repeated measurements were used to model the difference in PtGDA and PhGDA 
(PtGDA>PhGDA vs. PtGDA≤PhGDA). Gender patient, gender physician, age, swollen joint 
count, tender joint count, VAS pain, disease duration and ESR were considered as possible 
determinants in both models. 
 
Results 
Mean (SD) age was 57 (15) years and 67% of the patients were female. Agreement between 
PtGDA and PhGDA was moderate (ICC: 0.57). Patients scored on average 11 units higher 
(worse) than rheumatologists (95% limits of agreement: -25.2 to 47.6). Patient’s perception 
of pain (VAS) was positively associated with a PtGDA being higher than PhGDA. Similarly, 
ESR and swollen joint counts were positively associated with a PtGDA being lower or equal 
to the PhGDA.  
 
Conclusion 
Patients rate global disease activity consistently higher than their rheumatologists. Patients 






The importance and use of patient reported outcomes (PROs) in health care increased during 
the past decades. PROs are considered valuable in measuring status and change in health 
care.1 However, in addition to the PRO, similar information is also collected by the 
physician, e.g. assessment of level of disease activity. As patients and physicians may differ 
in their perception of health status, discordant observations may occur and may affect patient 
care. For example, patients are likely to report dissatisfaction with a treatment if their 
physician underestimates their perceived level of disease activity.2-4 The 100mm visual 
analogue scale (VAS) is an instrument used to measure global disease activity (GDA) in 
rheumatoid arthritis (RA). It can be completed by the patient (PtGDA) (and is considered 
then a PRO) as well as by the physician (PhGDA). Discordances between patients and 
rheumatologists rating their impression of GDA on a VAS have been reported; patients tend 
to score their GDA higher than their physician. Determinants reported to be of influence on 
the discrepancies between patients’ and physicians’ perceptions are pain, swollen joint count, 
tender joint count and erythrocyte sedimentation rate.5-7 However, the magnitude and 
direction of the influence of these factors is unclear. A determinant, to our knowledge not 
studied yet, which might be of influence on the difference between physicians’ and patients’ 
perception is the gender of the physician. This might be a plausible factor of difference in 
score since male and female physician perceptions differ in clinical practice regarding 
communication of information, compliance and satisfaction of the patient.8  
The METEOR (Measurement of efficacy of Treatment in the Era of Rheumatology) database 
provides data on several patient- and physician-reported outcome measures in RA, including 
gender of the rheumatologist. Here we have compared PtGDA and PhGDA reported in 





Data collected in the ongoing prospective international METEOR database were used. 
METEOR is an acronym for Measurement of efficacy of Treatment in the Era of 
Rheumatology hat has been started in 2008. METEOR is used by rheumatologists to monitor 
patients with rheumatic diseases. Data are collected in a central database in a completely 
39128 Gvozdenovic kopie.indd   70 19-02-16   17:55







To compare the patient’s (PtGDA) and physician’s (PhGDA) assessment of global disease 
activity and to identify factors that might influence these differences, as well as factors that 
may influence the patients and the physicians score separately. 
 
Methods 
Anonymous data were used from 2.117 Dutch patients included in the METEOR database. 
PtGDA and PhGDA were scored independently on a 100mm visual analogue scale (VAS) 
with 0 and 100 as extremes. The agreement, Intraclass correlation coefficients (ICC), was 
calculated and a Bland Altman plot was created to visualize the differences between PtGDA 
and PhGDA. Linear Mixed Model analysis was used to model PtGDA and PhGDA. Logistic 
repeated measurements were used to model the difference in PtGDA and PhGDA 
(PtGDA>PhGDA vs. PtGDA≤PhGDA). Gender patient, gender physician, age, swollen joint 
count, tender joint count, VAS pain, disease duration and ESR were considered as possible 
determinants in both models. 
 
Results 
Mean (SD) age was 57 (15) years and 67% of the patients were female. Agreement between 
PtGDA and PhGDA was moderate (ICC: 0.57). Patients scored on average 11 units higher 
(worse) than rheumatologists (95% limits of agreement: -25.2 to 47.6). Patient’s perception 
of pain (VAS) was positively associated with a PtGDA being higher than PhGDA. Similarly, 
ESR and swollen joint counts were positively associated with a PtGDA being lower or equal 
to the PhGDA.  
 
Conclusion 
Patients rate global disease activity consistently higher than their rheumatologists. Patients 






The importance and use of patient reported outcomes (PROs) in health care increased during 
the past decades. PROs are considered valuable in measuring status and change in health 
care.1 However, in addition to the PRO, similar information is also collected by the 
physician, e.g. assessment of level of disease activity. As patients and physicians may differ 
in their perception of health status, discordant observations may occur and may affect patient 
care. For example, patients are likely to report dissatisfaction with a treatment if their 
physician underestimates their perceived level of disease activity.2-4 The 100mm visual 
analogue scale (VAS) is an instrument used to measure global disease activity (GDA) in 
rheumatoid arthritis (RA). It can be completed by the patient (PtGDA) (and is considered 
then a PRO) as well as by the physician (PhGDA). Discordances between patients and 
rheumatologists rating their impression of GDA on a VAS have been reported; patients tend 
to score their GDA higher than their physician. Determinants reported to be of influence on 
the discrepancies between patients’ and physicians’ perceptions are pain, swollen joint count, 
tender joint count and erythrocyte sedimentation rate.5-7 However, the magnitude and 
direction of the influence of these factors is unclear. A determinant, to our knowledge not 
studied yet, which might be of influence on the difference between physicians’ and patients’ 
perception is the gender of the physician. This might be a plausible factor of difference in 
score since male and female physician perceptions differ in clinical practice regarding 
communication of information, compliance and satisfaction of the patient.8  
The METEOR (Measurement of efficacy of Treatment in the Era of Rheumatology) database 
provides data on several patient- and physician-reported outcome measures in RA, including 
gender of the rheumatologist. Here we have compared PtGDA and PhGDA reported in 





Data collected in the ongoing prospective international METEOR database were used. 
METEOR is an acronym for Measurement of efficacy of Treatment in the Era of 
Rheumatology hat has been started in 2008. METEOR is used by rheumatologists to monitor 
patients with rheumatic diseases. Data are collected in a central database in a completely 





anonymous way. Both newly diagnosed patients and patients with more advanced disease are 
included in de database. Measures of disease activity and Health Assessment Questionnaire 
data are registered every visit. Currently, the tool is used worldwide and data is available 
from 100 hospitals, which included more than 14.800 patients. More details on the METEOR 
database are described elsewhere.9 
A sample of 2.117 Dutch patients was taken from the METEOR database covering the time 
span between 2008 and 2011. The number of visits (8.509 in total) varied with a range of 1 to 
19 visits per patient as did time intervals between visits. PtGDA and PhGDA were measured 
on a 100mm visual analogue scale (VAS) with 0 (best possible) and 100 (worst possible) as 
extremes. PtGDA and PhGDA separately were operationalized as continuous variables. The 
20mm difference between PtGDA and PhGDA was used as a binary outcome variable 
(patient scores higher versus rheumatologist scores equal or higher). A difference in rating of 
20mm between PtGDA and PhGDA score was chosen as cut-off value, since it is considered 
to be a frequent chosen value for minimum clinically important improvement in PtGDA.5 
 
Statistical analyses 
Descriptive statistics were performed using the mean and standard deviation (SD) or median 
and interquartile ranges (IQR) as appropriate for continuous variables, and number and 
percentages for categorical variables. A Bland and Altman plot was performed to visualize 
the differences between PtGDA and PhGDA. This is based on the standard deviation of the 
differences in PtGDA and PhGDA calculated from variance components in a linear mixed 
model (LMM), and used to construct the 95% limits of agreement.9 The agreement between 
patient and physician was expressed as intraclass correlation coefficient (ICC) using variance 
components in a LMM with a random intercept for patients. LMM was also used to model 
the PtGDA and PhGDA. Gender patient, gender rheumatologist, age, swollen joint count, 
tender joint count, pain (VAS), disease duration (diagnosis until first visit) and erythrocyte 
sedimentation rate (ESR) were considered as possible determinants for the model. 
Furthermore LMM was used to estimate means of DAS28, ESR, tender and swollen joint 
count between male and female. Non-linear mixed modelling (repeated measures logistic 
regression) was used to model the difference in PtGDA and PhGDA as binary outcome 
(patient’s score higher than physician’s score as “event”). Gender patient, gender 
rheumatologist, age, swollen joint count, tender joint count, pain (VAS), disease duration and 
ESR were considered as possible determinants for the model. Software programs SAS 
 
 
version 9.2 and SPSS version 17.0 were used for the analyses and p-values smaller than 0.05 
were considered statistically significant. 
 
RESULTS 
Of the 2.117 patients, 1.338 (67%) were female. The mean (SD) age at entry was 57 (15) 
years (table 1).  
 
 




Age (years), mean (SD) 57 (15) 1879 
Patient female, n (%) 1339 (67) 2007 
Physician female, n (%) 1072 (67) 1598 
CRP, median (IQR) 5 (3 to 13) 167 
ESR, median (IQR) 14 (6 to 29) 1491 
DAS 28, mean (SD) 3.2 (1.4) 1408 
HAQ, median (IQR) 0.7 (0.1 to 1.4) 573 
Duration complaints until diagnosis (months), median (IQR) 4 (1 to 12) 855 
Duration complaints until first visit in METEOR (years), median 
(IQR) 
6 (1 to 14) 862 
Duration diagnosis until first visit in METEOR (years), median 
(IQR) 
3 (0 to 11) 996 
CCP positive, n (%) 215 (64) 334 
RF positive, n (%) 734 (77) 959 
Erosions present, n (%) 605 (66) 923 
Swollen joint count 28, median (IQR) 1 (0 to 3) 1799 
Tender joint count 28, median (IQR) 2 (0 to 4) 1799 
VAS (visual analogue scale),  median (IQR)   
Global disease activity physician 21 (10 to 41) 903 
Global disease activity patient 34 (14 to 55) 1615 
             Pain patient 39 (15 to 60) 1474 
n=number, SD=standard deviation, IQR= interquartile range, CRP=C-reactive protein, ESR= 
erythrocyte sedimentation rate, DAS28=Disease Activity Score 28 joints, HAQ= Health Assessment 
Questionnaire, CCP=cyclic cictrullinated ceptide antibody, RF=rheumatoid factor. 
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978 of the observed patient scores were higher (20mm) compared to the physicians score, 
2.747 of patients and physicians score where concordant (-20 mm until 20 mm) and 102 
patients score were lower (20 mm) than the physician’s score. 
Agreement between PtGDA and PhGDA was moderate (ICC: 0.57; p<0.01; 95% limits of 
agreement: -25.2 to 47.6). Patients rated their GDA on average 11mm higher (worse) than 
rheumatologists at the first registered visit. A few scores (n=19) showed a discrepancy 




















Figure 1. Bland and Altman’s plot; global disease activity patient (PtGDA) versus global disease 
activity physician (PhGDA) 
 
 
Both patients and physicians scored the GDA significantly higher when the number of tender 
joints, number of swollen joints, and VAS pain was higher (p<0.01).  Furthermore, a higher 
ESR (p<0.01) and male gender (p=0.02) were independently associated with a higher GDA 
score by the physician. Physician’s scores decreased by increasing disease duration (p=0.01). 
The gender of the physician was not associated with the GDA score by physician or patient 
(table 2). Pain (VAS), ESR and the number of swollen joints all independently were  
 
 
Table 2. Linear mixed model predictors of global disease activity by patients (PtGDA) and physicians 
(PhGDA) 
 PtGDA   PhGDA  
Variable Estimate β, (95% CI) p-value Estimate β, (95% CI) p-value 
Patient male 0.82 (-0.47 to 2.11) 0.21 1.86 (0.32 to 3.39) 0.02 
Physician male 0.58 (-0.55 to 1.71) 0.31 1.21 (-0.18 to 2.60) 0.09 
Age (years) 0.01 (-0.04 to 0.05) 0.82 -0.05 (-1.00 to 0.01) 0.08 
Disease duration (years) -0.05 (-0.12 to 0.01) 0.12 -0.10 (-0.17 to -0.02) 0.01 
ESR 0.02 (-0.01 to 0.05) 0.82 0.11 (0.07 to 0,14) <0.01 
Swollen joint count 28 0.87 (0.60 to 1.15) <0.01 3.24 (2.91 to 3.57) <0.01 
Tender joint count 28 0.41 (0.22 to 0.61) <0.01 0.75 (0.49 to 1.01) <0.01 
VAS pain patient 0.72 (0.69 to 0.74) <0.01 0.29 (0.26 to 0.32) <0.01 
CI=Confidence interval, β = beta, VAS=visual analogue scale, ESR= erythrocyte sedimentation rate. 
 
 
associated with the difference between patient’s GDA and physician’s GDA score. Patient 
scored GDA higher than their physician by increasing VAS pain (p<0.01); and physician 
scored GDA higher than the patient by increasing swollen joint count and ESR (p<0.01). 
Gender of the patient or gender of the physician did not have an effect on the difference 
between patient’s GDA and physician’s GDA score (table 3).  
 
 
Table 3. Non-linear mixed model predictors of global disease activity (GDA) difference between 
patients and physicians. 
 PtGDA (n=978)  versus PhGDA (2747)* 
Variable Estimate β, (95% CI) p-value 
Patient male -0.06 (-0.49  to 0.38) 0.79 
Physician male 0.17 (-0.23 to 0.59) 0.40 
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VAS pain patient 0.08 (0.05 to 0.11) <0.01 
*1= patient scores higher, 0= physician scores equal or higher; Reference category=0, VAS=visual 
analogue scale, ESR= erythrocyte sedimentation rate, CI=Confidence interval, β=beta. 
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Mean ESR and TJC28was lower in male patients compared to female patients (p=0.02). Also 
DAS28 was lower in male patients (p<0.01) (table 4). 
 
 
Table 4. Linear mixed models for means of DAS and DAS components between man and women 





On average, patients tend to score GDA systematically higher than rheumatologists. The 
agreement between patients and rheumatologists is only moderate. Physicians and patients 
both take into consideration tender joint count, swollen joint count and pain in their 
assessment of GDA. In addition, when rating GDA, the physician is influenced by the gender 
of the patient, disease duration and ESR. The difference in GDA score between patient and 
physician can best be explained by differences in pain, swollen joint count and ESR. 
Physicians put more weight on the value of ESR and SJC, whilst patients put more weight on 
pain. 
Patients and physicians take partly the same determinants in consideration when they assess 
global disease activity. The physician takes both ‘objective’ (swollen joint count, acute phase 
reactants and disease duration) and ‘subjective’ (patients’ pain and tender joint count) 
variables into account when assessing the GDA. Furthermore, physicians tend to rate GDA in 
male patients higher than in female patients. The latter finding might be related to the 
difference in perception of disease activity between male and female patients, since male 
patients tend to underestimate their disease activity compared to female patients.7 In our 
study male patients have indeed lower DAS and fewer tender joints when compared to 
female patients, while the number of swollen joints does not differ. This finding provides 
 Male 
Mean (95% CI) 
Female 
Mean (95% CI) 
 
p-value 
DAS28  2.8 (2.7 to 2.9) 3.1 (3.07 to 3.2) <0.01 
ESR  17.9 (16.5 to 19.3) 20.0 (19.3 to 21.0) 0.02 
Swollen joint count 28  1.6 (1.5 to 1.8) 1.5 (1.42 to 1.63) 0.38 
Tender joint count 28  2.3 (2.1 to 2.5) 2.6 (2.5 to 2.8) 0.02 
 
 
input to the suggestion that the physician may implicitly compensate for this difference by 
rating disease activity in higher than in female. 
The different factors patients and physician taken into consideration for their GDA 
assessment might be the explanation for the systematic difference in patients and physicians 
scores of almost 11 units (on a scale from zero to 100) and to the only moderate agreement 
between patients and physicians. Other studies also have reported discordances between 
patients and physicians in rating the GDA. Barton et al. showed that patients’ GDA score was 
on average 15 points higher than the physicians’ mean GDA score.10Also, the QUEST-RA 
study showed a higher mean GDA of patients (approximately 11 points) than GDA of 
physicians.5 In concordance with the latter study, we also found a difference of 
approximately 11 points. However, it is questionable if 11 points is a clinical relevant 
discrepancy between patient’ and physician’ GDA score since we defined 20 points to be a 
difference. On the other hand, the moderate agreement between patients and physicians might 
support that patients and physicians rate RA disease activity differently. This confirms the 
statement of an earlier study that patient and physicians differ in perception of disease 
activity.6 A previous study, carried out in several European countries, also showed only a 
moderate agreement between GDA patient and GDA physician.5 Other studies, performed in 
the United States and in Europe showed low correlations and low agreement between 
physician and global health assessments.11,12 The discrepancies between the results of 
previous studies might suggest differences between countries in GDA of patient and 
physician due to cultural factors. 
Our study shows that the difference in scoring might be explained by differences in the 
perception of ESR, swollen joints and pain. Pain is more likely to be associated with an equal 
or higher score of the patient. This statement was confirmed by the large QUEST-RA study, 
which studied factors on discordance between GDA of the patient and that of the physician. 
Pain was one of the most important factors that caused discordances. Pain increased 
significantly when patient scored GDA higher compared to the physician. Furthermore, the 
QUEST-RA also used 20mm difference in GDA score as the cut off value of a true difference 
between patient and physician.5 
In our study, patients with a high ESR and swollen joint count are more likely to be scored 
higher by the physician. A previous study confirms this result.10 Another study showed that, 
besides swollen joints, physician put more weight on ESR than patients.6 
As we can see from the results of our study, patients and physicians focus on different factors 
when assessing disease activity. Patients are more influenced by subjective feelings, such as 
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pain, while physicians base their score more on objective measures, such as number of 
swollen joints and ‘blood levels’. This is supported by previous literature.13 Patients base 
their assessments on needs, priorities, experiences, expectations and attitude, which are all 
subjective domains. Physicians, on the other hand, rely on the patient’s physical health status, 
which is considered more objective in nature.14,15 
This study has some limitations. The first is missing values, as these might not be randomly 
missing. Patients that perform worse in their opinion may stay at home and miss an 
appointment with the physician. This can result in selection of patients with unknown 
consequences. Another limitation is that the included patients were not always newly 
diagnosed RA patients. Some patients are already treated for years and patients expectations 
and perceptions can change as a result of improvement or worsening of their health.16 
Therefore, long treatment duration might influence patient’s assessment of GDA. 
In conclusion, patients and physicians both assess GDA using partly similar determinants. 
Differences in GDA scores may be explained by pain, ESR and swollen joint count. Patients 
put more weight on pain and physicians on ESR and swollen joint count. Also cultural 
differences may have contributed to the moderate level of agreement between patients and 
physicians. We already see a difference in agreement between patient’s and physician’s score 
by comparing studies performed in several countries. In clinical practice, it should be 
recommended to spend more time educating patients on how to rate the global disease 
activity. Patients need to be clearly informed on the difference between the disease activity 
and pain, as patients let pain influence their GDA score. A good understanding of the GDA 
score by the patient is important since a previous study showed that patients with a high 
PtGDA score, while having a normal ESR and low SJC and TJC, are not in remission.17 
Further research should be conducted to find out what the clinical impact is of these 
discrepancies between patients and physicians since previous research might suggest that 
treatment strategy is only based on the rheumatologist’s opinion and not on the patient’s 
opinion or the DAS28.18 Also differences in PtGDA and PhGDA score per country should be 
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To compare the differences between patient (Pt) and physician (Ph) global disease activity 
score (GDA) within and across 13 countries in the Measurement of efficacy of Treatment in 
the ‘Era of outcome’ in Rheumatology (METEOR) database. 
 
Methods 
Data from METEOR were used to compare PtGDA and PhGDA, scored independently on a 
100 mm visual analogue scale (VAS) from 0 (best possible) until 100 (worst possible), in 
23.117 visits in 5.709 anonymized patients during the period between 2008 and 2012. Linear 
Mixed Models (LMM) were used to model mean differences between PtGDA and PhGDA in 
13 countries (Brazil, Czech, France, Ireland, Italy, Latvia, Mexico, the Netherlands, Pakistan, 
Portugal, Spain, United Kingdom and the United States), adjusted for differences in DAS28. 
Generalized Estimating Equation (GEE) were used to model differences (>20mm) between 




Mean difference between PtGDA and PhGDA score varied by country, from -2mm 
(physician scores higher) in Mexico to +14mm (patient scores higher) in Brazil. ‘Country’ 
was a significant determinant of the difference between PtGDA and PhGDA score, 
independent of differences in DAS28. With Netherlands as reference, PtGDA and PhGDA 
scores for individual patients differ significantly in almost all (n=10) countries, with the 
exception of France and Spain. 
 
Conclusion 
Differences between patients’ and physicians’ assessment of global disease activity vary 
across the countries. Influence of country must be taken into account when interpreting 





The use of patient reported outcomes is valuable when measuring status and change in health 
care.1 Both the patient’s perception and the physician’s assessment of the disease play an 
important role in making treatment decisions and achieving therapeutic goals. However, 
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patients care.2-5 In rheumatoid arthritis (RA), the visual analogue scale (VAS) is used to rate 
global disease activity (GDA) on a scale from 0 to 100 millimeter (0 representing best, 100 
representing worst). The VAS can be used either as a patient reported outcome (patient GDA, 
PtGDA) or as a physician reported outcome (physician GDA, PhGDA). 
Previous studies have shown that patients and rheumatologists may differ in rating their 
impression on a GDA scale. These studies have suggested that patients tend to score GDA 
higher than their physicians, which suggests that patients and physicians take into account 
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However, it is not well known whether the country in which patient and physician live 
influences the discrepancy in GDA assessment. Differences between PtGDA and PhGDA 
may for example be dependent on the language used by patient and physician, but also on 
differences in the physician-patient relationship across different cultures.13,14 
The Measurement of efficacy of Treatment in the ‘Era of outcome’ of Rheumatology 
(METEOR) initiative has developed an online database that provides an easy to use program 
to register clinical data of RA patients monitored in daily practice. Anonymized data 
uploaded by participating rheumatologists in 13 countries on three continents were used to 
compare the mean differences between PtGDA and PhGDA within and across the 
Netherlands and 12 other countries on three continents.  
 
METHODS 
A cross-sectional study was conducted to investigate the influence of country on the 
difference between PtGDA and PhGDA. We used data from the METEOR database, a 
worldwide online tool for disease monitoring in RA. Clinical data on anonymized patients 
with newly diagnosed and patients with established RA of 26 countries and 81 hospitals are 
collected in this central database until 6 July 2012. A more detailed description of the 
METEOR database was published previously.11,15 
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For the current analysis, we selected countries for which at least 100 patient visits had been 
recorded in METEOR between 1 January 2008 and 6 July 2012: Brazil, Czech Republic, 
France Ireland, Italy, Latvia, Mexico, the Netherlands, Pakistan, Portugal, Spain, United 
Kingdom and the United States. There were 23.117 visits of 5.709 patients, ranging from 108 
to 6.718 visits per country and from 1 to 29 visits per patient containing both PtGDA and 
PhGDA scores. Patients rated the PtGDA and physicians rated the PhGDA on a 100mm VAS 
scale. The order in which the PtGDA and PhGDA were to be scored was not specified.  
A difference of  ≥20mm between PtGDA and PhGDA score was chosen as cut-off value for 
clinically relevant differences between patient and physician score and was dichotomously 
(yes versus no) evaluated.11 Country was defined as a categorical variable with Netherlands 
as a reference category, because it has provided the highest number (n=6.272) of patient data. 
We adjusted for DAS28 (based on four variables) status at the time of the visit, since disease 
activity can be a determinant of a difference between PtGDA and PhGDA.10,11 ‘Short’ or 
‘long’ disease duration was categorized according to the median disease duration of 2 years 
in this study and definitions in previous studies.16,17 
 
Statistical analysis 
A Bland and Altman plot was performed to visualize the differences between PtGDA and 
PhGDA among countries. A multilevel approach was followed to allow for the correlation 
between multiple visits within a subject. Mean GDA (the average of PtGDA and PhGDA) 
and the mean differences between PtGDA and PhGDA for each country were estimated using 
linear mixed models (LMM). LMM were also used to estimate the mean difference between 
PtGDA and PhGDA for gender and for disease duration stratified per country. Generalized 
estimated equations (GEE) were used to model a difference of 20 mm between PtGDA and 
PhGDA, with ‘country’ as a determinant and the Netherlands as reference category, adjusted 
for DAS28. Software program SPSS version 17.0 was used for the analyses and p-values 
smaller than 0.05 were considered statistically significant. 
 
RESULTS 
The numbers of PtGDA and PhGDA assessments (respectively) per country were as follows:  
Brazil: 1.220 and 1.195; Czech: 487 and 460; Spain: 238 and 244; France: 522 and 412; 
United Kingdom: 1.730 and 148; Ireland: 656 and 534; Italy: 3.987 and 3.747; Latvia: 135 
 
 
and 110; Mexico: 570 and 563; Netherlands: 17.923 and 6.804; Pakistan: 267 and 264, 
Portugal: 8.772 and 5.966; and United States: 2.025 and 1.939. Overall, patients scored GDA 
higher than physicians, resulting in an overall mean difference (mean (95% CI)) between 
PtGDA and PhGDA of +9 mm (95% CI: 8.9 to 9.4) (Patients score higher). Figure 1 shows 
the distribution of mean differences between PtGDA and PhGDA per country as a function of 
mean GDA in that country. The difference in scores between patient and physician was 
highest in Brazil (+14 (12.5 to 16.2) mm) while Mexico was the only country in which 
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Figure 1. Crude Mean difference (mm) between patient (PtGDA) and physician (PhGDA) global 
disease activity score per country. 
BR=Brazil, ES=Spain, PT=Portugal, NL=Netherlands, IT=Italy, US=United States, UK=United 
Kingdom, PK=Pakistan, CZ=Czech, MX=Mexico, FR=France, IE=Ireland, LT=Latvia. The size of 
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Latvia was the country with the highest mean values of both patient and physician GDA 
scores (51.8 (45.6 to 58)). Absolute mean values of PtGDA and PhGDA were lowest in 
Mexico (20.7 (15.2 to 26.2)) and in France (18.1 (15.2 to 21.1)). The differences between 
PtGDA and PhGDA stratified for males and females are shown in table 1. 
 
 
Table 1. Mean difference (mm) between patient (PtGDA) and physician (PhGDA) global disease 
activity score for men and women stratified by country 
 
Country 
PtGDA minus PhGDA 
 
p-value Male 
Mean (95% CI) 
Female  
Mean (95% CI) 
Brazil 14.1 (6.7 to 21.4) 14.4 (11.5 to 17.3) 0.93 
Czech -1.4 (-5.7 to 3.0) 0.65 (-2.5 to 3.8) 0.46 
Spain 7.9 (1.0 to 14.7) 12.9 (9.3 to 16.5) 0.20 
France 7.6 (3.3 to 11.8) 11.27 (8.9 to 13.7) 0.14 
United Kingdom 5.4 (3.3 to 7.6) 8.9 (7.7 to 10.1) <0.01 
Ireland 1.8 (-1.5 to 5.1) 1.6 (-0.3 to 3.5) 0.93 
Italy 5.8 (3.9 to 7.6) 8.0 (7.1 to 8.9) 0.04 
Latvia -1.6 (-9.6 to 6.6) 3.9 (1.1 to 6.7) 0.12 
Mexico -1.3 (-9.9 to 7.2) 0.2 (-1.3 to 1.7) 0.73 
Netherlands 7.7 (6.8 to 8.7) 10.2 (9.5 to 10.8) <0.01 
Pakistan 6.5 (-2.1 to 15.0) 5.7 (2.17 to 9.2) 0.86 
United States 4.7 (2.2 to 7.1) 5.4 (4.0 to 6.8) 0.63 
Portugal 10.2 (8.1 to 12.2) 12.0 (11.2 to 12.9) 0.10 
Overall  6.9 (6.2 to 7.6) 9.3 (8.9 to 9.7) <0.01 
CI=confidence interval. 
 
Physicians rated disease activity on average 6.9 (6.2 to 7.6) mm lower than male patients and 
9.3 (8.9 to 9.7) mm lower than female patients. We were not informed about the gender of the 
 
 
rating rheumatologist. The overall difference between men and women was statistically 
significant (p<0.01). Within countries, the difference between physicians and female patients 
is numerically higher than the difference between physicians and male patients. This was true 
for all countries except Ireland and Pakistan. These discrepancies reach statistical 
significance for the UK, the Netherlands and Italy. The overall mean difference between 
PtGDA and PhGDA also differed significantly for patients with ‘short’ vs. those with ‘long’ 
disease duration (table 2).  
 
 
Table 2. Mean difference (mm) between patient (PtGDA) and physician (PhGDA) global disease 
activity score for disease duration in years stratified by country 
Country 
PtGDA minus PhGDA 
p-value Dis Dur ≤2 year, 
mean (95% CI) 
Dis Dur >2 year, 
mean (95% CI) 
Brazil 11.4 (6.0 to 16.9) 15.9 (12.6 to 19.1) 0.12 
Czech -1.2 (-4.5 to 3.0) - - 
Spain 8.9 (0.5 to 17.3) 12.2 (6.6 to 17.7) 0.52 
France 4.7 (-4.5 to 13.8) 10.7 (8.4 to 12.9) 0.21 
United Kingdom 3.7 (-0.1 to 7.5) 9.0 (6.8 to 11.1) 0.02 
Ireland 1.0 (-2.3 to 4.2) 3.50 (0.8 to 6.2) 0.23 
Italy 7.1 (5.6 to 8.6) 6.7 (5.8 to 7.6) 0.58 
Latvia -0.5 (-6.3 to 5.3) 2.8 (-5.2 to 10.7) 0.47 
Mexico -1.8 (-4.3 to 0.9) - - 
Netherlands 9.8 (7.8 to 11.8) 8.8 (7.5 to 10.0) 0.37 
Pakistan 9.1 (3.4 to 14.7) 4.3 (0.3 to 8.4) 0.18 
United States 8.2 (5.5 to 10.9) 2.4 (0.4 to 4.4) <0.01 
Portugal 11.2 (8.8 to 13.5) 12.4 (11.5 to 13.3) 0.31 
Overall  6.9 (6.0 to 7.9) 9.1 (8.6 to 9.6) <0.01 
CI=confidence interval. Dis Dur=disease duration 
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Patients with a short disease duration scored on average 6.9 (6.0 to 7.9) mm higher than their 
physician, while patients with a longer disease duration scored on average 9.3 (8.9 to 9.7) 
mm higher than their physician (p<0.01) for the difference between short and long disease 
duration). Within the countries, significant differences between short and long disease 
duration in PtGDA versus PhGDA score were present in the UK and in the United States. In 
the UK, differences between PtGDA and PhGDA were smaller when disease duration was 
short (3.7, (-0.1 to 7.5) mm) compared to long (9.0 (6.8 to 11.1) mm). In the United States the 
opposite was observed: differences between PtGDA and PhGDA were on average smaller 
when disease duration was long (2.4 (0.35 to 4.4) mm), as compared to short (8.2 (5.5 to 
10.9) mm).  
  
 
Table 3. Difference (20mm) between patient (PtGDA) and physician (PhGDA) global disease activity 
score (yes/no), comparison between countries* 
 Difference present (n=6.190) versus difference absent (n=14.684) 
Country, visits (n) PtGDA 
higher 
PhGDA higher OR (95% CI) p-value 
Brazil (958) 342 (36) 71 (7) 1.63 (1.33 to 2.00) <0.01 
Czech (457) 60 (13) 46 (10) 0.70 (0.53 to 0.93) 0.01 
Spain (193) 47 (24) 2 (1) 0.92 (0.62 to 1.37) 0.69 
France (396) 106 (27) 2 (0) 1.18 (0.91 to 1.54) 0.22 
United Kingdom (1.076) 221 (21) 28 (3) 0.61 (0.51 to 0.73) <0.01 
Ireland (475) 59 (13) 39 (8) 0.59 (0.46 to 0.76) <0.01 
Italy (3.414) 742 (22) 99 (3) 0.75 (0.65 to 0.88) <0.01 
Latvia (105) 6 (6) 5 (5) 0.17 (0.07 to 0.40) <0.01 
Mexico (445) 31 (7) 30 (7) 0.37 (0.26 to 0.52) <0.01 
Pakistan (160) 44 (28) 23 (14) 1.70 (1.13 to 2.56) 0.01 
Portugal (5.526) 1837 (33) 207 (4) 1.35 (1.22 to 1.50) <0.01 
United States (1.397) 280 (20) 77 (6) 0.85 (0.72 to 1.00) 0.05 
* Reference category= Netherlands (n visits=6.272), corrected for DAS28 (Disease Activity Score for 
28 joints), n=number, CI=confidence interval, OR=Odds Ratio. 
 
 
In databases of the Czech Republic and Mexico, only patients with short disease duration 
were recorded in the METEOR database. In both of these countries, physicians scored global 
disease activity on average higher than the patients. Table 3 shows, by country, the likelihood 
(in odds ratios) that a difference in GDA between physician and patient of more than 20mm 
was found, relative to the Netherlands corrected for DAS28. Among RA patients from the 
Netherlands who enrolled in the METEOR database, 28% of the visits showed a discrepancy 
of at least that magnitude. In Brazil, Pakistan and Portugal the likelihood of a discrepancy of 
at least that magnitude was higher than in the Netherlands, whereas in the UK, Ireland, Italy, 
Latvia, Mexico, Czech Republic and the United States this likelihood was lower. Table 3 also 
shows the number of times that the patient scored higher (20mm) than the physician and vice 




The analyses described in this study report the influence of country of residence on the 
comparison of patients’ and physicians’ assessments of global disease activity in RA. While 
we have investigated already such differences in the Netherlands only,11 we now have 
described patterns in 13 different countries all over the world. In these countries, the patient 
usually rated his or her global disease activity to be worse than did the assessing physician.  
With the Netherlands as reference, we found clinically relevant differences between 
physicians’ and patients’ ratings in almost all countries, except for France and Spain. The 
magnitude to which these patient-reported and physician-reported GDA deviates varies per 
country. Gender differences seem to contribute, reaching statistical significance in Italy, 
Netherlands and the United Kingdom. The relationship between disease duration and 
patient/physician discrepancy is more heterogeneous across countries but may also contribute 
to overall differences between countries.  
Since DAS28 is likely to be associated with a difference between PtGDA and PhGDA, we 
adjusted for DAS28. Even after correction, country of residence appeared to be a determinant 
of discrepancy in assessment of global disease activity between patient and physician, 
making it more likely that there is a true country-specific influence. Our finding that the 
difference between PtGDA and PhGDA varies by country has important implications. Multi-
national observational studies, in which patient-reported outcomes are analyzed, may be 
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In databases of the Czech Republic and Mexico, only patients with short disease duration 
were recorded in the METEOR database. In both of these countries, physicians scored global 
disease activity on average higher than the patients. Table 3 shows, by country, the likelihood 
(in odds ratios) that a difference in GDA between physician and patient of more than 20mm 
was found, relative to the Netherlands corrected for DAS28. Among RA patients from the 
Netherlands who enrolled in the METEOR database, 28% of the visits showed a discrepancy 
of at least that magnitude. In Brazil, Pakistan and Portugal the likelihood of a discrepancy of 
at least that magnitude was higher than in the Netherlands, whereas in the UK, Ireland, Italy, 
Latvia, Mexico, Czech Republic and the United States this likelihood was lower. Table 3 also 
shows the number of times that the patient scored higher (20mm) than the physician and vice 




The analyses described in this study report the influence of country of residence on the 
comparison of patients’ and physicians’ assessments of global disease activity in RA. While 
we have investigated already such differences in the Netherlands only,11 we now have 
described patterns in 13 different countries all over the world. In these countries, the patient 
usually rated his or her global disease activity to be worse than did the assessing physician.  
With the Netherlands as reference, we found clinically relevant differences between 
physicians’ and patients’ ratings in almost all countries, except for France and Spain. The 
magnitude to which these patient-reported and physician-reported GDA deviates varies per 
country. Gender differences seem to contribute, reaching statistical significance in Italy, 
Netherlands and the United Kingdom. The relationship between disease duration and 
patient/physician discrepancy is more heterogeneous across countries but may also contribute 
to overall differences between countries.  
Since DAS28 is likely to be associated with a difference between PtGDA and PhGDA, we 
adjusted for DAS28. Even after correction, country of residence appeared to be a determinant 
of discrepancy in assessment of global disease activity between patient and physician, 
making it more likely that there is a true country-specific influence. Our finding that the 
difference between PtGDA and PhGDA varies by country has important implications. Multi-
national observational studies, in which patient-reported outcomes are analyzed, may be 





interpreted in the context of cultural differences between countries, or alternatively in the 
context of ethnicity.18 This is in line with findings in some previous studies. It has been 
shown that the disease burden by patients differs per country.19-22 Several studies have 
demonstrated a large variation between countries in the prevalence of low back pain and 
chronic pain.19 Gureje et al. showed that the prevalence of chronic pain is relatively high in 
South American countries, such as Brazil, compared to Asian countries.19 Besides, RA-
patients may have concomitant fibromyalgia syndrome that may explain excess of pain.24,25 
In our study, Brazil was the country with the largest differences between patient’s and 
physician’s GDA score. Patients scored on average 14 mm higher than their physician, which 
might share similar origins with the higher prevalence of chronic pain in Brazil.26 Along 
similar lines, patients from the Mediterranean have been shown to report more pain than 
patients living in Northern and Western Europe.27 The findings of our study show similar 
trends: a greater discrepancy between PtGDA and PhGDA, resulting from patients scoring 
higher disease activity than their physicians, was observed in Portugal and Spain than in 
Ireland and the United Kingdom. These differences in patient-reported vs physician-assessed 
disease burden is difficult to explain. Cross-cultural differences may play a role, just as ethnic 
differences. Alternatively, different expectations about the disease RA between physicians 
and patients may play a role.28 
In three countries we have also found associations between gender and the differences in 
GDA scores between patients and their physicians. In the United Kingdom, the Netherlands 
and Italy the discrepancy between PtGDA and PhGDA was significantly higher for women 
than for men, while the direction of the difference was the same in males and females 
(patients scored higher than physicians). In each of the other 10 countries these gender 
differences were not statistically significant, but were in the same direction in all countries 
except Ireland and Pakistan. Pooling the data of all 13 countries resulted in statistically 
significant gender associations. These associations pertained to small effects (differences of 
+2mm) but at least suggest that the country where patient and physician reside should be 
taken into account when comparing gender differences in GDA assessment. We should 
further not rule out measurement error as potential explanations when looking at such small 
differences. Previous studies have also suggested gender differences with regard to patient 
reported outcomes in multiple countries. In general, female patients often report more pain 
and higher disease activity compared to men, both within- and across countries.29 
We found longer disease duration to be associated with different patient’s and physician’s 
GDA assessment in two countries; The United States and the United Kingdom. Further 
 
 
studies should elucidate if this association is true (and requires explanation) or based on 
statistical artifacts. As said, pooling the data of all 13 countries yielded a mean difference of 
only 2 mm, which appears not to be very important, especially since the differences within 
countries are heterogeneous. 
A strength of this study was the availability of a large number of patients and visits, which 
increases the power of the study. A limitation is the cross-sectional nature of the study, which 
does not allow to assess cause and effect. In addition, PtGDA and PhGDA were not assessed 
independently, which may have influenced the differences in scores between countries. Also, 
the patients entered into the METEOR database do not represent a random sample of the 
population of RA patients in each country. The number of visits available for analysis varied 
by country from 105 to 6.200, which might result in less reliable conclusions drawn from 
data collected in countries in which there were only small numbers of visits. Furthermore, 
data of physical functioning and comorbidities, which may also influence the perception of 
GDA (by patient and physician), were often not reported in METEOR and could not be 
adjusted for. A last limitation to be mentioned is that PtGDA and PhGDA in this database 
with data obtained in regular clinical practice (without pre-specified protocol) may not have 
been obtained independently; the physician most often must have been aware of the patient’s 
judgement when giving his own judgement. This is inherent to common clinical practice and, 
even though it may decrease rather than increase a difference between PtGDA and PhGDA, 
precludes a robust scientific explanation for the observed differences.   
In conclusion, differences between patient’s and physician’s assessment of global disease 
activity are partly dependent on the country in which the patient and the physician reside. In 
some countries, these differences are related to gender and disease duration, while this is not 
so obvious in others. Our findings may have implications for generalizing international data. 
There may be restrictions as to what extent we can combine and interpret data obtained in 
different countries. The influence of country must be further investigated and taken into 
account when interpreting discordances between the patient’s and the physician’s assessment 
of global disease activity in RA and perhaps also when incorporating these scores into 
recommendations regarding decision algorithms on medication use, such as Treat-to-Target 
strategies.  
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Little is known on how well targeted treatment, for instance targeting towards low DAS, is 
implemented in clinical practice. Our aim was to evaluate treatment adjustments in response 
to DAS in RA patients in clinical practice.  
 
Methods 
We used data from one referral centre, multiple rheumatologists, from the METEOR 
database. Generalized Estimating Equations (GEE) were used to assess whether in case of 
non-low disease activity (DAS>2.4) treatment intensifications in DMARD therapy occurred 
(change or increase in dose or number of DMARDs, including synthetic (s)DMARDs, 
biologic (b)DMARDs and corticosteroids compared to the visit before). Determinants of not 
intensifying the treatment when DAS>2.4 were investigated using GEE. 
 
Results 
5.157 registered visits of 1.202 patients were available for the analyses. A DAS>2.4 was 
weakly (OR: 1.19; 95%CI 1.07 to 1.33) associated with a treatment intensification. In 69% 
(n=3.577) of the visits patients were in low disease activity. In 66% (n=1.028) of the visits 
with DAS>2.4 treatment was not intensified. These patients had a higher tender joint count 
and received more often methotrexate plus a bDMARD, or csDMARD monotherapy, as 
compared to patients that received treatment intensification.  
 
Conclusion 
In the majority of visits in the METEOR database patients were already in a state of low 
disease activity, reflecting appropriate treatment intensity. When DAS was greater than 2.4, 
treatment was often not intensified due to high tender joint count or specific treatment 
combinations. This data suggest that while aiming for low DAS, physicians per patient weigh 
whether all DAS elements indicate disease activity or will respond to DMARD adjustment or 





The aim of treatment in rheumatoid arthritis (RA) is to achieve low disease activity or 
remission using a ‘treat to target’ (tight control) approach in which the disease activity of 
patients is monitored intensively and measured frequently with composite measures.1-3 
Treatment intensity can be adjusted by changing DMARDs or by increasing the dose and/or 
number of anti-rheumatic drugs, including synthetic (s)DMARDs and biologic (b)DMARDs 
and corticosteroid.4 Since treatment to target and tight control have been proven to result in 
better clinical and radiological outcomes than routine care,5-11 these concepts are at the basis 
of the current recommendations for the management of rheumatoid arthritis in daily practice. 
When sustained remission or low disease activity is achieved and medication is tapered or 
discontinued and following patients and tight control is important as half of the patient may 
flare with decreasing medication.12,13 Despite the fact that rheumatologists have reported to 
use treat-to-target in daily practice,14-16 some studies have suggested that targeted treatment 
may not be widely practiced yet17,18. Besides, it is well known that limited adherence to 
guidelines is prevalent in many chronic conditions, such as atrial fibrillation, hypertension 
and osteoporosis.19-21 
We used the Measurement of Efficacy of Treatment in the ‘Era of Outcome’ in 
Rheumatology (METEOR) database,22 to investigate the association between level of the 
DAS and whether or not physicians adjusted treatment with sDMARDs and bDMARDs and 




For the current cross-sectional analyses we have used data from METEOR, which is an 
international prospective database aiming to improve tight monitoring and treatment to target 
in patients with rheumatic diseases. METEOR started in 2008 and is used as an online daily 
practice tool for rheumatologists to collect clinical data and calculate disease activity, 
registering the effectiveness of their treatment practice over time in patients with RA.  
Data of both patients with advanced disease and with newly diagnosed RA were collected in 
a central database. Data is uploaded anonymously and therefore an ethics statement is not 
required for this study. A more detailed description of the METEOR database was published 
previously.22,23 We have used data from the Leiden University Medical Center (LUMC) since 
39128 Gvozdenovic kopie.indd   100 19-02-16   17:55







Little is known on how well targeted treatment, for instance targeting towards low DAS, is 
implemented in clinical practice. Our aim was to evaluate treatment adjustments in response 
to DAS in RA patients in clinical practice.  
 
Methods 
We used data from one referral centre, multiple rheumatologists, from the METEOR 
database. Generalized Estimating Equations (GEE) were used to assess whether in case of 
non-low disease activity (DAS>2.4) treatment intensifications in DMARD therapy occurred 
(change or increase in dose or number of DMARDs, including synthetic (s)DMARDs, 
biologic (b)DMARDs and corticosteroids compared to the visit before). Determinants of not 
intensifying the treatment when DAS>2.4 were investigated using GEE. 
 
Results 
5.157 registered visits of 1.202 patients were available for the analyses. A DAS>2.4 was 
weakly (OR: 1.19; 95%CI 1.07 to 1.33) associated with a treatment intensification. In 69% 
(n=3.577) of the visits patients were in low disease activity. In 66% (n=1.028) of the visits 
with DAS>2.4 treatment was not intensified. These patients had a higher tender joint count 
and received more often methotrexate plus a bDMARD, or csDMARD monotherapy, as 
compared to patients that received treatment intensification.  
 
Conclusion 
In the majority of visits in the METEOR database patients were already in a state of low 
disease activity, reflecting appropriate treatment intensity. When DAS was greater than 2.4, 
treatment was often not intensified due to high tender joint count or specific treatment 
combinations. This data suggest that while aiming for low DAS, physicians per patient weigh 
whether all DAS elements indicate disease activity or will respond to DMARD adjustment or 





The aim of treatment in rheumatoid arthritis (RA) is to achieve low disease activity or 
remission using a ‘treat to target’ (tight control) approach in which the disease activity of 
patients is monitored intensively and measured frequently with composite measures.1-3 
Treatment intensity can be adjusted by changing DMARDs or by increasing the dose and/or 
number of anti-rheumatic drugs, including synthetic (s)DMARDs and biologic (b)DMARDs 
and corticosteroid.4 Since treatment to target and tight control have been proven to result in 
better clinical and radiological outcomes than routine care,5-11 these concepts are at the basis 
of the current recommendations for the management of rheumatoid arthritis in daily practice. 
When sustained remission or low disease activity is achieved and medication is tapered or 
discontinued and following patients and tight control is important as half of the patient may 
flare with decreasing medication.12,13 Despite the fact that rheumatologists have reported to 
use treat-to-target in daily practice,14-16 some studies have suggested that targeted treatment 
may not be widely practiced yet17,18. Besides, it is well known that limited adherence to 
guidelines is prevalent in many chronic conditions, such as atrial fibrillation, hypertension 
and osteoporosis.19-21 
We used the Measurement of Efficacy of Treatment in the ‘Era of Outcome’ in 
Rheumatology (METEOR) database,22 to investigate the association between level of the 
DAS and whether or not physicians adjusted treatment with sDMARDs and bDMARDs and 




For the current cross-sectional analyses we have used data from METEOR, which is an 
international prospective database aiming to improve tight monitoring and treatment to target 
in patients with rheumatic diseases. METEOR started in 2008 and is used as an online daily 
practice tool for rheumatologists to collect clinical data and calculate disease activity, 
registering the effectiveness of their treatment practice over time in patients with RA.  
Data of both patients with advanced disease and with newly diagnosed RA were collected in 
a central database. Data is uploaded anonymously and therefore an ethics statement is not 
required for this study. A more detailed description of the METEOR database was published 
previously.22,23 We have used data from the Leiden University Medical Center (LUMC) since 





at the time of evaluation the data of this site were most complete with information on both 
DAS outcomes and anti-rheumatic treatment. Patients were included in METEOR between 
January 2008 and May 2013. We have selected 1.202 patients (5.157 visits ranging from 1 to 
31 visits per patient) where DAS (5.157 visits) as well as information on treatment were 
available. 
 
Outcome variables and determinants 
Treatment adjustment was divided into three categories; 1) dose decrease (either a lower dose 
or fewer sDMARDs or bDMARDs or corticosteroids, including intra articular injections,  
compared to the previous visit), 2) stable dose (the same sDMARDs or bDMARDs or 
corticosteroids, including intra articular injections, and the same dose compared to the 
previous visit) and 3) treatment change or intensification (higher dose or more or other 
sDMARDs or bDMARDS or corticosteroids, including intra articular injections, compared to 
the previous visit).  
DAS was classified in four categories, according to the EULAR classification criteria 
(DAS<1.6 representing clinical remission, DAS>1.6 and ≤2.4 representing low disease 
activity, DAS>2.4 and ≤3.7 representing moderate disease activity, and DAS>3.7 
representing high disease activity). For secondary analyses DAS was divided in two 
categories; DAS ≤2.4 and DAS>2.4. 
 We used hypothetical conditions, based on a previous study, in which there was a 
discrepancy between components of the DAS representing inflammation (joint swelling, 
laboratory results) or pain (potentially regardless of inflammation) as secondary outcomes.24 
These conditions included 1) cases in which a patient had ≤1 swollen joints but 2 or more 
tender joints 2) cases in which a patient had  ≤1 swollen joints but reported a high disease 
activity (≥20 on a visual analogue scale, VASpt) 3) cases in which a patients had ≤ 1 swollen 
joints but an erythrocyte sedimentation rate (ESR) ≥ 28 mm/hr 4) cases in which VASpt was 
≥20mm higher than the physician’s score of the patients global disease activity (VASphys) 
and 5) cases in which the VASphys was  ≥20mm higher than the VASpt.23-25 
 
Statistical analyses 
Descriptive statistics were performed using median and interquartile ranges (IQR) for 
continuous variables, and number and percentages for categorical variables.  
 
 
The association between DAS and treatment adjustments was assessed using generalized 
estimating equations (GEE) in order to adjust for the spurious effects of repeated 
measurements and treatment adjustments within the same subject. The probability of a 
treatment outcome (decreased, stable or change/intensified) was modelled using the GEE 
ordinal (cumulative) regression analysis approach.26 In the regression model, treatment 
adjustment was the dependent variable, with increase of treatment being the last ordinal 
category (reference). DAS>2.4 (yes or no) was used as the determinant. We tested the 
proportional odds for treatment adjustment with crude calculations in cross tables and the 
goodness-of-fit test. These did not indicate a violation of the proportional odds assumption.27 
In a set of subanalyses, a first GEE binary logistic regression was performed to compare 
decreased dose versus stable dose. A second binary GEE was performed to compare 
decreased dose versus increased dose; and a third binary GEE analysis was performed to 
compare increased dose versus stable dose. In all three analyses DAS>2.4 was the 
determinant. A fourth GEE was performed to model patients with DAS>2.4 (no 
intensification versus intensification of treatment) as dependent variable, with erythrocyte 
sedimentation rate (ESR), SJC, VASpt (patient assessment of global disease activity), TJC 
and actual treatment as determinants. This model was corrected for gender and age.  
SPSS version 17.0 was used for the analyses and a two-sided p-value less than 0.05 was 
considered statistically significant. 
 
RESULTS 
In total 5.157 registered visits in 1.202 patients who were treated with sDMARDs and/or 
bDMARDs and/or corticosteroids, were available for the analyses. Mean age was 56 (SD: 14) 
and disease duration was on average 17 months (IQR: 3 to 84). 71% (n=854) of the 
population were women (table 1). In 1.580 of these 5157 visits (31%) DAS was >2.4 (and in 
4% of these, DAS was >3.7), in 3577 visits (69%), DAS was ≤2.4 (in 39% of these DAS was 
<1.6). In 1.692/5.157 visits (33%) medication was intensified, in 2.881 visits (56%), 
medication was kept stable, and in 584 visits (11%) medication was tapered or discontinued 
(table 2). GEE showed that on patient level a higher DAS was only weakly but yet 
statistically significantly correlated with a change/increase in medication (OR: 1.19, 95%CI: 
1.07 to 1.33, table 3). The binary logistic GEE regression showed that in patients with a 
DAS>2.4 treatment was more often changed/intensified (OR: 1.30, 95%CI: 1.05 to 1.60) than 
tapered, but not significantly more often changed/intensified than kept stable (table 3). 
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Table 1. Baseline characteristics (visit 1) for patients in the METEOR database.  
 Total patients, n=1.202 
Female, n (%) 854 (71) 
Age (years), mean (SD) 56 (14) 
Disease duration (months), median (IQR) 17 (3 to 84) 
CCP positive, n (%)  407 (71) 
RF present, n (%) 722 (75) 
DAS, mean (SD) 2.5 (1.1) 
HAQ, mean (SD) 1.0 (0.7) 
ESR, median (IQR) 19 (9 to 34) 
RAI, median (IQR) 4 (1 to 7) 
SJC, median (IQR) 3 (0 to 7) 





39 (19 to 59) 
21 (10 to 40) 
43 (23 to 64) 
n=number, SD=standard deviation, IQR= interquartile range, VAS=visual analogue scale, CRP= C-
reactive protein, ESR= erythrocyte sedimentation rate, DAS=Disease Activity Score, RAI=Ritchie 
Articular Index, HAQ= Health Assessment Questionnaire, CCP=cyclic cictrullinated peptide 
antibody, RF=rheumatoid factor 
 
 
In only 552/1.580 (35%) of the visits in which the patient had a DAS>2.4 medication was 
indeed changed/intensified, and this percentage was not higher in patients with a DAS>3.7 
(table 2).  
 
 
Table 2. Number of visits with decreased, stable or increased dose per level of disease activity based 
on DAS (Disease Activity Score). 







DAS Remission: < 1.6, n (%) 257 (13) 1149 (56) 629 (31) 2035 (100) 
 LDA: 1.6 - 2.4, n (%) 179 (12) 852 (55) 511 (33) 1542 (100) 
 MDA: 2.4 - 3.7, n (%) 125 (9) 770 (56)  479 (35) 1374 (100) 
 HDA: > 3.7, n (%) 23 (11) 110 (53) 73 (35) 206 (100) 
n=number, LDA=low disease activity, MDA=moderate disease Activity, HDA=high disease activity. 
 
 
In 23 visits (11%) in which patients had high disease activity (DAS>3.7) the dose was even 
decreased. In comparison, in 629 of the 2.035 visits (31%) where patients were in remission 
(DAS<1.6) medication was still changed/intensified (table 2).  
 
 
Table 3. Association between DAS (Disease Activity Score) and treatment adjustment in METEOR  
*Reference category is a DAS ≤ than 2.4. ** Ordinal and *** binary generalized estimating equation 
regression analysis. DAS > 2.4: higher odds to increase treatment. ß=beta, CI=confidence interval. 
 
 
In the 1.028/1.580 (65%) visits in which patients had a DAS>2.4 treatment was nevertheless 
not changed/intensified. On the visit level we investigated whether there were discrepancies 
in DAS components in these 1.028 visits by comparing the median (interquartile range, IQR) 
tender joint count, swollen joint count, ESR and patient VAS: the median for tender joint 
count (6, IQR 2 to 8) was slightly higher than the median for swollen joint count (median 4, 
IQR 2 to 8) (table 4).  
 
 
Table 4. Median of DAS components in visits where medication is not increased when patients have 
moderate/high disease activity. 
 DAS>2.4 and medication not increased 
 n=1.028 visits, median (IQR) 
VASpt  60.0 (46.0-72.8) 
Swollen joint count   4.0 (2.0-8.0) 
Tender joint count  6.0 (4.0-8.0) 
ESR  25.0 (11.0-38.0)* 
* n=1 missing visit for ESR. n= number, IQR= interquartile range, ESR= erythrocyte sedimentation 
rate, VASpt=Patient assessment of Global Disease Activity. 
 DAS>2.4* 
 ß OR (95% CI) 
Overall ordinal correlation**  0.175 1.19 (1.07-1.33) 
Stable versus decreased dose*** 0.259 1.30 (1.05-1.60) 
Increased versus stable dose*** 0.096 1.10 (0.97-1.26) 
Increased  versus decreased dose*** 0.36 1.43 (1.17-1.74) 
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In 20% of the visits in which DAS was >2.4 and medication was not changed/intensified, SJC 
was low (≤1) while TJC and patient’s VAS for global disease activity were high (≥2 or ≥20, 
respectively). A higher patient-reported- than physician-assessed global disease activity 
(difference in VAS ≥20mm) was found in 33% of these visits (table 5). 
 
 
Table 5. Number of visits in which there are discrepancies in DAS components in patients with 
moderate/high disease activity that did not receive treatment intensification.  
 DAS>2.4 and medication not increased              
n (%) Total  
SJC ≤1 and TJC ≥2 201 (19.6) 1028 
SJC ≤1 and VASpt  ≥20 198 (19.3) 1028 
SJC ≤1 and ESR ≥28 98 (9.5) 1027 
VASpt ≥20 mm higher than VASphys 148 (32.9) 450 
VASphys ≥ 20 mm higher than VASpt 25 (5.6) 450 
ESR= erythrocyte sedimentation rate, VASpt= patient assessment of global disease activity, 




In a GEE binary logistic regression we checked in patients with a DAS>2.4 which factors 
were associated with NO intensification of treatment (intensification of treatment=reference), 
corrected for age and gender. 
These factors were (high) tender joint count (OR: 1.05, 95%CI: 1.01 to 1.10), current 
treatment with conventional synthetic (cs) DMARD monotherapy (OR: 3.28, 95%CI: 2.40 to 
4.48) and combination therapy with methotrexate (MTX) and a bDMARD (OR: 1.93, 
95%CI: 1.25 to 2.98) (table 6).  Finally, we checked on a visit level whether an improvement 
in DAS was found compared to the previous visit, but also at the following visits. However, 
we did not have drug data on all the previous and following visits. In 82 of the available 874 
visits (9%) there had been an improvement in DAS (EULAR (European League Against 
Rheumatism) response moderate or good)) compared to the previous visit (table 7).  
After a high DAS was followed with no change or increase in medication, at the following 




Table 6. Determinants for not increasing medication when patients have moderate/high disease 
activity, measured by a generalized estimating equation binary logistic regression.* 
 DAS>2.4: medication is not increased vs medication is 
increased (n=1.574 visits) 
ß OR (95%CI) P-value 
ESR 0.00 1.00 (0.99 to 1.01) 0.86 
SJC -0.02 0.99 (0.96 to1.01) 0.20 
VASpt 0.00 1.00 (0.99 to1.01) 0.98 
TJC 0.05 1.05 (1.01-1.10) <0.01 
Actual drug**    
DMARD monotherapy 1.19 3.28 (2.40 to 4.48) <0.01 
MTX + bDMARD 0.66 1.93 (1.25 to 2.98) <0.01 
DMARD combination therapy 0.12 1.12 (0.83 to 1.53) 0.46 
DMARD + prednisone 0.03 1.03 (0.67 to 1.57) 0.90 
*Analysis is corrected for gender and age. ** Reference category = other drugs. ESR= erythrocyte 
sedimentation rate, SJC= swollen joint count, TJC=tender joint count, VasPtGlobal=Patient 
Assessment of global disease activity. 
 
 
Table 7. Number of visits in which patients show improvement in DAS according to the EULAR 
criteria. 
 DAS>2.4, medication  
not increased              Total 
DAS improvement compared to the previous visit   
None: ≤0.6, N (%) 792 (91) 874 
Moderate: 0.6-1.2, N (%) 60 (7) 874 
Good: >1.2, N (%) 22 (2) 874 
DAS improved in the following visit   
None: ≤0.6, N (%) 236 (83) 283 
Moderate: 0.6-1.2, N (%) 33 (12) 283 
Good: >1.2, N (%) 14 (5) 283 
DAS=Disease Activity Score, EULAR= European League Against Rheumatism. 
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In this analysis from daily practice observations collected in the METEOR database, we 
obtained information about how the treat to target recommendation in RA is followed in a 
single large academic referral centre (LUMC). Most patients had low disease activity or 
remission (69% of visits DAS=<2.4, 39% even <1.6) during the majority of visits. These 
percentages approach figures that have been reported in treat-to-target studies such as 
CAMERA,28 DREAM29 and BeSt30 in which 50-82% achieved low disease activity or 
remission.  
This observation, together with the apperception that DAS-results were indeed measured and 
recorded, support a conclusion that rheumatologists in the LUMC follow the treat to target 
approach in daily practice quite well. Since rheumatologists working in the LUMC conducted 
the Best study, which aims at low disease activity using DAS-steered therapy, this could be 
expected. Many previous studies, such as TICORA, GUEPARD and ESPOIR showed that a 
treat to target strategy leads to better clinical outcomes compared to routine care.5,8 
Since questionnaire-based studies suggest that rheumatologists are aware of the advantages of 
treatment to target and are willing to apply the treatment recommendations,14-16  the 
METEOR tool was developed to help and stimulate rheumatologists to apply a treat to target 
approach in daily practice.  
In spite of a high percentage of patients with DAS<2.4, we also found on a patient level, that 
DAS>2.4 itself was only weakly associated with a change or intensification of antirheumatic 
medication (OR: 1.19). In comparison to tapering the dose if DAS was ≤2.4, the likelihood of 
increasing the dose was only marginally higher in patients with a DAS >2.4. Furthermore, per 
visit where treatment was not intensified although DAS was higher than 2.4 we found 
discrepancies in subjective patient outcomes (high tender joint count and/or high patient 
reported global disease activity on a visual analogue scale) versus physician assessment of 
disease activity (low swollen joint count). This is reflected by an OR for tender joint count of 
1.05 (CI95Q% 1.01-1.1) for not intensifying medication in case of DAS>2.4.  
This observation may suggest that although rheumatologist may steer treatment decisions by 
the measured DAS, they consider other explanations of high DAS components, for instance 
secondary fibromyalgia or irreversible joint damage as explanation for a high tender joint 
count, which may not respond to a further increase of anti-inflammatory drugs. A 
discrepancy between subjective patient outcomes and objective physician assessments has 
been shown in earlier METEOR studies focused on patient’s global disease activity (GDA). 
 
 
Here we found that when patients rate their GDA, they base their opinion more on subjective 
signs (patient’s perception of pain), while physicians put more weight on objective signs 
(swollen joint count, ESR) when rating GDA of the patient. Also is shown that discrepancies 
between patients and physicians in GDA assessment are different among countries, 
suggesting that reporting and acknowledging pain differs per country.23,31 The METEOR 
database does not contain information on damage or secondary pain syndromes, or indeed 
other comorbidities, which may also have held rheumatologists back in increasing treatment 
where the DAS was high. Nor do we have information on reasons why patients may not have 
wanted to increase medication.  
We also found that the likelihood of treatment intensification in case of DAS>2.4 was less if 
the patient was currently using csDMARD monotherapy, which may indicate a reluctance 
among patients to change or expand medication,32 or methotrexate in combination with a 
biological agent. The latter may indicate that rheumatologists may be reluctant to change the 
biologic, as it is currently unclear which is the optimal treatment choice if the first biologic is 
ineffective.33-35 Previous studies suggest that an important reason for the rheumatologist to 
not (yet) intensify the treatment was that they anticipated further improvement on the current 
medication. We tested this hypothesis but we found only in 9% of the available visits clinical 
relevant improvement in DAS. 
An important limitation to this study is that we do not have data on comorbidities, which 
might influence the decision of the rheumatologist to change or not change the treatment. 
Furthermore, we used a rather broad categorization of treatment adjustment without any 
hierarchy in for instance type or number of drugs that were adjusted, which may have 
influenced the results. Another limitation is that we have no imaging data, although presence 
or absence of radiologic damage progression, in clinical practice can influence the decision 
on treatment intensification. A final restriction is that we used only data form the LUMC 
since data of other centers/countries were not (sufficiently) available yet. These results may 
therefore not be generalizable to all patients treated in clinical practice, since perception of 
pain seems to be country dependent. 
In conclusion, we have found a high percentage of patients with remission or a low level of 
disease activity in the majority of regular registered visits of RA patients to the outpatient 
clinic of a large academic hospital in the Netherlands. We have also found that a moderate- to 
high disease activity does not automatically lead to treatment intensification, which may still 
suggest that Treat-to-Target and EULAR recommendations for the management of patients 
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with RA are well followed, but also that the doctor is looking critically at possible reasons for 
elevation of elements of the DAS before deciding on treatment intensification. Future 
research is needed to study the relationship between disease activity and treatment adjustment 
using different categorizations, such as type of medication. Also, it will be useful to 
understand how comorbidities influence the relationship between treatment adjustment and 
disease activity.  
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To investigate if rheumatologists that report to follow up guidelines really do this by 
monitoring practice performance in clinical practice. 
 
Methods 
Data of the International Recommendation Implementation Study (IRIS) is used, which 
included 132 participating rheumatologists from 14 countries. Participants received a 
questionnaire measuring their awareness/commitment with the EULAR/T2T recommendations, 
followed by an educational program. They were asked to include and monitor 5-10 new-onset 
RA patients in the IRIS database for a period of 1-2 years. 
 
Results 
In total, 72 of the 132 participants have added 378 patients in the database. Of these 
participants 70 (98%) agreed that DMARD-therapy should be started as soon as possible after 
diagnosis in every patient and 69 (96%) agreed that methotrexate should be part of the first 
treatment strategy. Treatment changes according to these recommendations were reported in 
253 (67%) and 225 (60%) of the recorded patients, respectively. Of the participants 60 (83%) 
agreed that composite measures should be recorded regularly, while in 134 (54%) of the 
patients composite scores were recorded in ≥50% of patient visits. 
 
Conclusion 
Reporting to follow EULAR recommendations and T2T principles after an educational 




During the last decades, many guidelines and recommendations have been formulated with the 
aim to improve the quality of care.1-5 In rheumatology, international recommendations for the 
management of patients with rheumatoid arthritis (RA) focus on treatment decisions including 
the choice of initial therapy and subsequent alternatives, on monitoring disease activity as a 
measure of treatment success and on reasons for treatment adjustments. Besides, they 
emphasise shared decision making, patient education, how to deal with comorbidities and the 
role of specialized nurses in the treatment care of RA. 
These recommendations include concepts of ‘treating-to-target’ (further referred to as T2T) 
and ‘tight control’. The treat-to-target approach requires that patients will receive medication, 
and if necessary intensification or adjustment of therapy, until a predefined treatment goal (a 
certain level of disease activity, often clinical remission or low disease activity) is achieved. 
The ‘tight control’ concept requires frequent assessments of disease activity in order to check if 
the treatment goal has been achieved and to avoid delays in optimal treatment. It is 
recommended that monitoring disease activity should be done by composite measures (DAS, 
DAS28, SDAI and CDAI).6-8 
In many surveys rheumatologists report that they follow the recommendations for RA in 
clinical practice.9-11Although, some studies suggest that recommendations are not practiced yet 
outside of clinical trials.12,13 These studies indicate that there is a discrepancy between 
reporting agreement with recommendations and actual performance in clinical practice 
(implementation). Only a few studies have shown a successful implementation of 
recommendations, such as treat to target, and suggestions to improve DAS steered therapy in 
clinical practice.14,15 Many obstacles may postpone a successful implementation, such as a lack 
of awareness and lack of agreement,16-18 or lack of treatment-protocols.15 A previous study has 
shown that educational programs may effectively help to implement clinical guidelines in 
practice.19 
In order to test the efficacy of such an implementation initiative, the International 
Recommendation Implementation Study (IRIS) was initiated. As part of this study we have 
investigated whether rheumatologists that report to follow the European League Against 
Rheumatism (EULAR) recommendations on the management of RA and the T2T 
recommendations really do this in clinical practice. In order to increase the chance of 
successful implementation, we have provided them a web-delivered educational program.  
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IRIS is a 2-year follow-up implementation study in which rheumatologists received a 
questionnaire on their awareness of-, agreement with- and adherence to the EULAR/T2T 
recommendations formulated in 2010 (see attachment I and II).6,8 
The questionnaire started with general questions about whether participating rheumatologists 
were aware of the recommendations and whether they follow them in clinical practice. Then, 
we asked per recommendation whether they follow it in clinical practice. Participants were able 
to choose three options for answering the questions: ‘yes’, ‘for some patients/sometimes’ or 
‘no’. The answers on whether the participants were applying the following four EULAR and 
Treat to target recommendations in clinical practice were used in this study:  
 ‘Treatment with synthetic DMARDs should be started as soon as the diagnosis of RA is 
made’ 
 ‘MTX is part of the first treatment strategy’ 
 ‘When MTX contraindications (or intolerance) are present, the following DMARDs 
should be used: Leflunomide, sulfasalazine or injectable gold’ 
 ‘Measures of disease activity must be obtained and documented regularly as frequently 
as monthly for patients with high/moderate disease activity or less frequently (such as 
every 3–6 months) for patients in sustained low disease activity or remission’ 
After completing the questionnaire, participating rheumatologists took part in a short education 
programme on these recommendations, consisting of reading two articles on the EULAR 
recommendations for the management of RA and the T2T recommendations and watching an 
online video in which the principles of the recommendations and the aims of IRIS were 
explained by expert rheumatologists and researchers. It was also optional to follow an online 
training to get familiar with the Measurement of efficacy of Treatment in the Era of Outcome 
of Rheumatology (METEOR) registration tool. After this, they were required to record data on 
disease monitoring and adjustment of treatment in 5-10 patients with newly diagnosed RA per 
rheumatologist. Registration took place in METEOR,20,21 which is a large online database 
developed for rheumatologists providing an online  tool to register data from RA patients and 
monitor them in daily practice. The patients were followed for 1-2 years. During this follow-up 
period participating rheumatologists received every month one of the EULAR/T2T 
 
 
recommendation per email to remind them on the study and to encourage them to follow all the 
recommendations in clinical practice. 
We compared the proportion of rheumatologists that agreed with the EULAR and T2T 
recommendations with the proportion of their patients who were actually treated according to 
these recommendations in clinical practice. 
From December 2011 rheumatologists worldwide were approached via their national RA 
societies to participate in IRIS. 132 rheumatologists from the following 14 countries agreed to 
participate in this study: Bosnia, Brazil, Croatia, Cyprus, Greece, Italy, Malta, the Netherlands, 
Nigeria, Poland, Portugal, Russia, Spain, and Turkey. The first rheumatologist started with the 
educational program in March 2012 and the final participant started in February 2014.The 
database is still ongoing and will close 2 years after the last participant added the last patient 
(February 2016). 
The participants have received a payment of 250 euro per included patient to compensate for 
the work in this study. 
 
Outcome variables 
We compared how often rheumatologists agreed with the following four recommendations 
with how the proportion of their patients actually treated according to these recommendations:  
  EULAR recommendation 1: ‘Treatment with synthetic DMARDs should be started as 
soon as the diagnosis of RA is made’. We determined the proportion of patients in 
whom the time interval between the date of diagnosis and the date of start of a DMARD 
(disease-modifying anti rheumatic drug) was <= 4 weeks.  
 EULAR recommendation 2: ‘MTX is part of the first treatment strategy in patients with 
active RA’. We determined the proportion of RA patients in whom MTX was (part of) 
the first treatment strategy.  
 EULAR recommendation 3: ‘When MTX contraindications (or intolerance) are 
present, the following DMARDs should be used: Leflunomide, sulfasalazine or 
injectable gold’. We determined the proportion of patients that did not start with MTX 
in whom leflunomide, sulfasalazine or injectable gold was prescribed.  
 Treat to Target recommendation 5: ‘Measures of disease activity must be obtained and 
documented regularly as frequently as monthly for patients with high/moderate disease 
activity or less frequently (such as every 3–6 months) for patients in sustained low 
disease activity or remission’. We created three categories: ‘T2T always’ represents the 
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number of patients for whom a composite score (DAS, DAS28, CDAI or SDAI) was 
reported at least every 2 months during moderate or high disease activity (DAS>2.4, 
DAS28>3.6 CDAI>10, SDAI>11) and at least every 7 months for low disease activity 
in 100% of the visits. A patient was categorized as ‘T2T sometimes/never’ when this 
was found in some or none of the visits, with an estimation of the percentage of visits in 
which the recommendation was followed. A category ‘not reported’ reflects patients in 
whom composite scores were missing in all of the visits.  
 
RESULTS 
Of the 132 participating rheumatologist who agreed participation in the IRIS, 122 (92%) 
completed the questionnaire, finished the web-based educational program and were followed 
for 1-2 years. During the follow-up period 72 (55%) of the participating rheumatologists have 
recorded 1155 visits from 378 newly diagnosed patients in the database prospectively. The 
remaining participants dropped out (n=44) or were lost to follow-up (n=6) before including 
patients in the METEOR database (Figure 1).  
Reasons for dropping out of the study where lack of time to participate or withdrawn consent 
with regard to participation in the study. The remaining 72 rheumatologists were from the 
following countries: Bosnia, Cyprus, Greece, Italy, the Netherlands, Nigeria, Russia and Spain. 
We compared the results of the questionnaire from 72 rheumatologists who entered patients in 
the database with the 50 rheumatologists who did not, and found that agreement was similar 
between the two groups (Attachment I and II).  
Of the 72 participating rheumatologists 70 (98%) had reported to be compliant with the 
recommendation ‘Treatment with synthetic DMARDs should be started as soon as the 
diagnosis of RA is made’ (table 1). In 253 of the 378 (67%) patients that were recorded in the 
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Table 1. Comparison between agreement with the EULAR and Treat to Target recommendations and 
managing patients in clinical practice 
 Rheumatologists opinion  
about adherence  
(measured in 72  
Rheumatologists)* 
Rheumatologists performance in 
daily practice 




















EU 1. ‘Treatment with 
synthetic DMARDs should 
be started as soon as the 
diagnosis of RA is made’. 






EU 3. ‘MTX is part of the 













EU 4. ‘When MTX 
contraindications (or 
intolerance) are present, the 
following DMARDs 
should be used: 
Leflunomide, sulfasalazine 
of injectable gold’. 






T2T ‘Measures of disease 
activity must be obtained 
and documented 
regularly’*** 
60 (83) 10 (14) 2 (3) 68 (27) 125 (51) 
23 in ≥75% 
45 in ≥50%  
27 in <50 %  
30 in 0 of the 
visits  
54 (22) 
* Always = rheumatologists report to follow this recommendation, sometimes/never= rheumatologist 
report to follow this recommendation sometimes or not, missing = no answer was filled in **Always = 
rheumatologists follow this recommendation, sometimes/never = rheumatologist follow this 
recommendation sometimes or not. Not reported= no information present on whether the 
recommendation is followed by the rheumatologist. *** As frequently as monthly for patients with 
high/moderate disease activity or less frequently (such as every 3–6 months) for patients in sustained 
low disease activity or remission. EU=EULAR recommendation. T2T=treat-to-target recommendation, 
MTX=methotrexate, DMARD=disease-modifying anti rheumatic drug. 
 
 
In 50 of the 378 patients (13%) a DMARD was not started within 4 weeks, but after a median 
(interquartile range) period of 13 (7 to 57) weeks (table 2). For 60 of the 378 patients (1%) 
essential information was missing (date of diagnosis/ or date of start first DMARD). 
 
 
Table 2. Average time from diagnosis (weeks) until a patient received a first DMARD in those patients 
in whom a DMARD was NOT started within 4 weeks after diagnosis 
 Patients (n=65) 
(n, %) 
Average time to start per 
therapy (median, IQR) 
Methotrexate 41 (82) 13 (7 to 57) 
Hydroxychloroquine  6 (12) 12 (1 to 606) 
Sulfasalazine 1 (2) 10  
Leflunomide 2 (4) 189 resp 245 weeks 
No DMARD started 15 (23) - 
IQR= interquartile range 
 
 
Of the 72 participating rheumatologists, 69 (96%) had reported that they are compliant with the 
recommendation ‘MTX is part of the first treatment strategy’. In 225 of the 378 patients (60%) 
MTX has indeed been prescribed as (part of) the first treatment. Of the 93 patients (26%) who 
did not start with MTX 15 (19%) have received leflunomide, sulfasalazine or injectable gold as 
first treatment, but 78 patients (81%) have started with other medications (table 3). Of the 
participating 72 rheumatologists, 60 (83%) had reported that they are compliant with the 
recommendation: ‘Measures of disease activity must be obtained and documented regularly as 
frequently as monthly for patients with high/moderate disease activity or less frequently (such 
as every 3–6 months) for patients in sustained low disease activity or remission’. Of the 378 
patients 131 had less than 2 visits. For those patients with more than one visit recorded (247) 
we could check whether patients were monitored according to this recommendation. Of these 
247 patients 68 (27%) had been monitored in full accordance with this recommendation, and 
were in the ‘T2T always’ group. 
Another 23 (9%) patients had been monitored in partial accordance with this recommendation 
(75-100% of the visits) and were in the ‘T2T sometimes’ group. 45 (18%) patients had been 
monitored but insufficiently (in 50-75% of the visits) and also assigned to the ‘sometimes’ 
group (table 1). 
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Table 3. Medication prescribed as initial treatment and average time in weeks from diagnosis until start, 
in patients in whom MTX, leflunomide, Sulfasalazine or injectable gold was NOT started as first 
DMARD  
 Patients (n total=78) 
(N, %) 
Average time in weeks to start 
per therapy (median, IQR) 
Hydroxychloroquine (+/- NSAID) 12 (15) 0 (0 to 0) 
Parental corticosteroid (+/- HCQ) 28 (36) 0 (0 to 0) 
Oral corticosteroid ( +/- HCQ) 28 (36) 0 (0 to 3) 
NSAID/analgetics 3 (4) 0 (0 to 0) 
Ciclosporin 1 (1) 0 (0 to 0) 
Biologic DMARD  6 (8) 64 (4 to 245) 
IQR = interquartile range, NSAID=nonsteroidal anti-inflammatory drug, HCQ= Hydroxychloroquine, 
DMARD=disease-modifying anti rheumatic drug 
 
 
27 (11%) patients were poorly monitored (<50% of the visits) and also in the ‘sometimes’ 
group (table 1). Finally 30 (13%) of the patients were in the ‘T2T never’ group where 
monitoring in none of the visits was done according to the recommendation. 
 
DISCUSSION 
The main conclusion of this study conducted in rheumatologists practicing in different parts of 
the world is that reporting to follow four EULAR/T2T recommendations does not mean that 
these recommendations are actually applied in daily clinical practice. We have found 
discrepancies between what rheumatologists report to do versus how they actually treat patients 
in clinical practice.  
In our study less than 60% of the recruited rheumatologists that agreed to participate, 
expectedly the more dedicated rheumatologists, finished both the educational program and 
included patients in the METEOR database, which is rather disappointing. Yet even after 
participating in a dedicated educational program, in which those rheumatologists were actively 
stimulated to follow recommendations, which proved in many previous studies to have a 
positive effect on actually implementing recommendations,19,22-24 rheumatologists still seem to 
be reluctant to follow up that recommendation. In fact, they report that they follow up 
recommendations, but act differently in clinical practice. What could potentially explain this 
 
 
discrepancy? First, trivial logistic explanations may account. For instance, a patient may not 
show up for a visit, which in turn could lead to missing disease activity data within the 
recommended time period. Furthermore, there might be a time gap in obtaining knowledge on 
recommendations and actually implementing them. Rheumatologists might agree with 
recommendations and feel stimulated by an educational program to follow them, but time is 
too short to actually change practice (1-2 years follow- up). In the study by Forsetlund et al. 
physicians that were actively stimulated to treat patients according to evidence-based practice 
were compared with physicians that only received access to evidence based libraries, but no 
significant differences between the groups in behaviour of decision making was found. Their 
follow-up was 1.5 year, which was argued not to be long enough to change decision-making 
among physicians.25 A Dutch study also showed discrepancies between compliance with- and 
actual application of recommendations about mental health in practice. However, in this study 
no educational program was used to encourage physicians to follow the recommendations.26 
An important strength of this study is that we have used study participants stemming from all 
over the world which increases generalizability. There are also limitations of this study. First of 
all, we investigated the agreement and adherence to the EULAR recommendations of 2010, 
which were new at the time of study initiation but have been updated since then (online 
publication in October 2013, while inclusion and instruction in the current study was finished 
in March 2013). However, the updated recommendations did not differ much with respect to 
the 4 recommendations studied. The only difference that is relevant for the interpretation of 
this study is that injectable gold is not recommended anymore when MTX is contraindicated. 
Another limitation is that we miss information about characteristics of the  participating 
rheumatologists, due to privacy reasons. While rheumatologists from all over the world have 
participated in the study, we are still uncertain whether the study is fully generalizable to all 
rheumatologists. A more technical explanation for not following the recommendations in 
clinical practice is that we based our verdict about whether the recommendations were 
followed on the registration of rheumatologists’ actions in the METEOR database. It is 
possible that recommendations were followed more often than was recorded. However, all 
rheumatologists were informed of this procedure when they agreed to participate in this study, 
were instructed to register their performance in the METEOR database and have been offered a 
training program to optimally use that database. We are not sure whether the participating 
rheumatologists have actually completed the educational program, so it is difficult to conclude 
that the program has influenced the behaviour of the rheumatologists. We did sent out monthly 
emails with a recommendation in order to remind the rheumatologist on the project, which has 
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Table 3. Medication prescribed as initial treatment and average time in weeks from diagnosis until start, 
in patients in whom MTX, leflunomide, Sulfasalazine or injectable gold was NOT started as first 
DMARD  
 Patients (n total=78) 
(N, %) 
Average time in weeks to start 
per therapy (median, IQR) 
Hydroxychloroquine (+/- NSAID) 12 (15) 0 (0 to 0) 
Parental corticosteroid (+/- HCQ) 28 (36) 0 (0 to 0) 
Oral corticosteroid ( +/- HCQ) 28 (36) 0 (0 to 3) 
NSAID/analgetics 3 (4) 0 (0 to 0) 
Ciclosporin 1 (1) 0 (0 to 0) 
Biologic DMARD  6 (8) 64 (4 to 245) 
IQR = interquartile range, NSAID=nonsteroidal anti-inflammatory drug, HCQ= Hydroxychloroquine, 
DMARD=disease-modifying anti rheumatic drug 
 
 
27 (11%) patients were poorly monitored (<50% of the visits) and also in the ‘sometimes’ 
group (table 1). Finally 30 (13%) of the patients were in the ‘T2T never’ group where 
monitoring in none of the visits was done according to the recommendation. 
 
DISCUSSION 
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in clinical practice.  
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discrepancy? First, trivial logistic explanations may account. For instance, a patient may not 
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recommendations and actually implementing them. Rheumatologists might agree with 
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in March 2013). However, the updated recommendations did not differ much with respect to 
the 4 recommendations studied. The only difference that is relevant for the interpretation of 
this study is that injectable gold is not recommended anymore when MTX is contraindicated. 
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clinical practice is that we based our verdict about whether the recommendations were 
followed on the registration of rheumatologists’ actions in the METEOR database. It is 
possible that recommendations were followed more often than was recorded. However, all 
rheumatologists were informed of this procedure when they agreed to participate in this study, 
were instructed to register their performance in the METEOR database and have been offered a 
training program to optimally use that database. We are not sure whether the participating 
rheumatologists have actually completed the educational program, so it is difficult to conclude 
that the program has influenced the behaviour of the rheumatologists. We did sent out monthly 
emails with a recommendation in order to remind the rheumatologist on the project, which has 





been shown to be an effective tool in previous implementation studies.27 Furthermore, we have 
offered the educational program via the internet, while a more effective approach could have 
been telephone interviews or educational visits to the physician. Some reviews have suggested 
that multifaceted strategies, such as educational meetings, educational resources and support 
from colleagues, are more successful strategies to assist in implementation of 
recommendations,28-31 although another review suggested that it is not clear yet which 
implementation strategies are best.32 A reluctance to record daily practice in the METEOR 
database, which is user-friendly20 may explain why only 72 (55%) of the rheumatologists 
finished the educational program and included patients. When we compared the agreement 
with the recommendations between the rheumatologists that dropped out after the educational 
program (n=50) with the 72 participants that effectively included patients, the responses were 
similar. Technical or other problems with data entry in the METEOR database may also have 
led to incompleteness of data. In 16-22% of patient data information was not reported on the 4 
studied recommendations. We do not know if these patients are randomly missing, and if 
entered data are inconsistent. In addition, we can only speculate about the reasons for not 
complying with recommendations, as additional data on treatment steps, contraindications for 
medication, side effects and comorbidities are not recorded.   
In conclusion, the results of this study show that there is a discrepancy between agreeing with 
well-known and broadly accepted recommendations on treating-to-target, timing and choice of 
initial treatment as well as tight control in the management of patients with rheumatoid arthritis 
on one hand, and the actual performance in clinical practice when measured. A dedicated 
internet-based educational program might be insufficient to change the attitude of the 
rheumatologists. This observation has implications for the broadly advocated recommendation 
to implement quality-control initiatives in order to make practice performance more 
transparent: It looks as if the development and publication of evidence and consensus-based 
treatment recommendations do not suffice to change practice performance in rheumatology. 
Since these recommendations are usually a trade-off between best evidence and cost-
effectiveness, it can be argued if nowadays patients with RA are indeed optimally treated in 
clinical practice. Further studies should focus on factors that explain the reluctance of 
rheumatologists to follow evidence based treatment recommendations, in particular reluctance 
of MTX prescription in patients with co-morbidities, and on strategies to overcome this 
reluctance. In addition, future studies should focus on investigating what type of education is  
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Attachment I. EULAR recommendations for the management of RA, differences between 
participating rheumatologists and rheumatologists that stopped or were lost to follow-up during the 
study. 





Are you aware of the recommendations? N, % 72 (100) - 50 (100) - 
Are you following the recommendations?  58 (81) 14 (19) 38 (76) 12 (24) 
1. Treatment with synthetic DMARDs should be started as 
soon as the diagnosis of RA is made 
70 (99) 1 (1) 48 (96) 2 (4) 
2. Treatment should be aimed at reaching a target of 
remission or low disease activity as soon as possible in 
every patient; as long as the target has not been reached, 
treatment should be adjusted by frequent (every 1–3 
months) and strict monitoring. 
64 (90) 7 (10) 47 (94) 3 (6) 
3. MTX should be part of the first treatment strategy in 
patients with active RA 
69 (97) 2 (3) 47 (94) 3 (6) 
4. When MTX contraindications (or intolerance) are 
present, the following DMARDs should be considered as 
part of the (first) treatment strategy: leflunomide, SSZ 
or injectable gold. 
59 (83) 12 (17) 42 (84) 8 (16) 
 
5. In DMARD naïve patients, irrespective of the addition of 
GCs, synthetic DMARD monotherapy rather than 
combination therapy of synthetic DMARDs may be 
applied. 
56 (79) 15 (21) 
 
41 (82) 9 (18) 
6. GCs added at low to moderately high doses to synthetic 
DMARD monotherapy (or combinations of synthetic 
DMARDs) provide benefit as initial short-term 
treatment, but should be tapered as rapidly as clinically 
feasible. 
64 (90) 7 (10) 43 (86) 6 (14) 
7. If the treatment target is not achieved with the first 
DMARD strategy, addition of a biological DMARD 
should be considered when poor prognostic factors are 
present; in the absence of poor prognostic factors, 
switching to another synthetic DMARD strategy should 
be considered 
60 (85) 11 (15) 39 (78) 11 (22) 
8. In patients responding insufficiently to MTX and/or 
other synthetic DMARDs with or without GCs, 
biological DMARDs should be started; current practice 
would be to start a TNF inhibitor (adalimumab, 
certolizumab, etanercept, golimumab, infliximab) which 
should be combined with MTX 
61 (86) 10 (14) 41 (82) 9 (18) 
9. Patients with RA for whom a first TNF inhibitor has 
failed, should receive another TNF inhibitor, abatacept, 
rituximab or tocilizumab 
67 (94) 4 (65) 45 (90) 5 (10) 
 
10. In cases of refractory severe RA or contraindications to 
biological agents or the previously mentioned synthetic 
DMARDs, the following synthetic DMARDs might be 
also considered, as monotherapy or in combination with 
some of the above: azathioprine, ciclosporin A (or 
exceptionally, cyclophosphamide) 
49 (69) 22 (31) 32 (64) 18 (36) 
11. Intensive medication strategies should be considered 
in every patient, although patients with poor prognostic 
factors have more to gain. 
67 (94) 4 (6) 42 (86) 7 (14) 
 
12. If a patient is in persistent remission, after having 
tapered GCs, one can consider tapering biological 
DMARDs, especially if this treatment is combined with a 
synthetic DMARD 
54 (76) 17 (24) 37 (76) 12 (24) 
13. In cases of sustained long-term remission, cautious 
titration of synthetic DMARD dose could be considered, 
as a shared decision between patient and doctor 
61 (86) 10 (14) 43 (88) 6 (12) 
 
14. DMARD naïve patients with poor prognostic markers 
might be considered for combination therapy of MTX 
plus a biological agent 
47 (86) 10 (14) 31 (63) 18 (37) 
 
15. When adjusting treatment, factors apart from disease 
activity, such as progression of structural damage, 
comorbidities and safety concerns should be taken into 
account 
69 (97) 2 (3) 
 





Attachment II. Treat to target, differences between participating rheumatologists and 
rheumatologists that stopped during the study. 





Are you aware of the recommendations? N, % 70 (97) 2 (3) 47 (96) 2 (4) 
Are you following the recommendations?  55 (79) 15 (21) 31 (66) 16 (34) 
 
1. The primary target for treatment of rheumatoid 
arthritis should be a state of clinical remission. 
65 (93) 5 (7) 41 (93) 3 (7) 
2. Clinical remission is defined as the absence of signs and 
symptoms of significant inflammatory disease activity. 
68 (97) 2 (3) 39 (89) 5 (11) 
3. While remission should be a clear target, based on 
available evidence low disease activity may be an 
acceptable alternative 
67 (96) 3 (4) 42 (95) 2 (5) 
4. Until the desired treatment target is reached, drug 
therapy should be adjusted at least every 3 months. 
65 (93) 5 (7) 37 (84) 7 (16) 
5. Measures of disease activity must be obtained and 
documented regularly, as frequently as monthly for 
patients with high/moderate disease activity or less 
frequently (such as every 3–6 months) for patients in 
sustained low disease activity or remission 
60 (86) 10 (14) 31 (70) 13 (30) 
6. The use of validated composite measures of disease 
activity, which include joint assessments, is needed in 
routine clinical practice to guide treatment decisions. 
65 (93) 5 (7) 39 (89) 5 (11) 
7. Structural changes and functional impairment should 
be considered when making clinical decisions, in 
addition to assessing 
64 (91) 6 (9) 41 (93) 3 (7) 
8. The desired treatment target should be maintained 
throughout the remaining course of the disease. 
65 (93) 5 (7) 37 (84) 7 (16) 
9. The choice of the (composite) measure of disease activity 
and the level of the target value may be influenced by 
consideration of co-morbidities, patient factors and 
drug-related risks. 
67 (96) 3 (4) 38 (86) 6 (14) 
10. The patient has to be appropriately informed about the 
treatment target and the strategy planned to reach this 
target under the supervision of the rheumatologist. 
65 (93) 5 (7) 41 (93) 3(7) 
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soon as the diagnosis of RA is made 
70 (99) 1 (1) 48 (96) 2 (4) 
2. Treatment should be aimed at reaching a target of 
remission or low disease activity as soon as possible in 
every patient; as long as the target has not been reached, 
treatment should be adjusted by frequent (every 1–3 
months) and strict monitoring. 
64 (90) 7 (10) 47 (94) 3 (6) 
3. MTX should be part of the first treatment strategy in 
patients with active RA 
69 (97) 2 (3) 47 (94) 3 (6) 
4. When MTX contraindications (or intolerance) are 
present, the following DMARDs should be considered as 
part of the (first) treatment strategy: leflunomide, SSZ 
or injectable gold. 
59 (83) 12 (17) 42 (84) 8 (16) 
 
5. In DMARD naïve patients, irrespective of the addition of 
GCs, synthetic DMARD monotherapy rather than 
combination therapy of synthetic DMARDs may be 
applied. 
56 (79) 15 (21) 
 
41 (82) 9 (18) 
6. GCs added at low to moderately high doses to synthetic 
DMARD monotherapy (or combinations of synthetic 
DMARDs) provide benefit as initial short-term 
treatment, but should be tapered as rapidly as clinically 
feasible. 
64 (90) 7 (10) 43 (86) 6 (14) 
7. If the treatment target is not achieved with the first 
DMARD strategy, addition of a biological DMARD 
should be considered when poor prognostic factors are 
present; in the absence of poor prognostic factors, 
switching to another synthetic DMARD strategy should 
be considered 
60 (85) 11 (15) 39 (78) 11 (22) 
8. In patients responding insufficiently to MTX and/or 
other synthetic DMARDs with or without GCs, 
biological DMARDs should be started; current practice 
would be to start a TNF inhibitor (adalimumab, 
certolizumab, etanercept, golimumab, infliximab) which 
should be combined with MTX 
61 (86) 10 (14) 41 (82) 9 (18) 
9. Patients with RA for whom a first TNF inhibitor has 
failed, should receive another TNF inhibitor, abatacept, 
rituximab or tocilizumab 
67 (94) 4 (65) 45 (90) 5 (10) 
 
10. In cases of refractory severe RA or contraindications to 
biological agents or the previously mentioned synthetic 
DMARDs, the following synthetic DMARDs might be 
also considered, as monotherapy or in combination with 
some of the above: azathioprine, ciclosporin A (or 
exceptionally, cyclophosphamide) 
49 (69) 22 (31) 32 (64) 18 (36) 
11. Intensive medication strategies should be considered 
in every patient, although patients with poor prognostic 
factors have more to gain. 
67 (94) 4 (6) 42 (86) 7 (14) 
 
12. If a patient is in persistent remission, after having 
tapered GCs, one can consider tapering biological 
DMARDs, especially if this treatment is combined with a 
synthetic DMARD 
54 (76) 17 (24) 37 (76) 12 (24) 
13. In cases of sustained long-term remission, cautious 
titration of synthetic DMARD dose could be considered, 
as a shared decision between patient and doctor 
61 (86) 10 (14) 43 (88) 6 (12) 
 
14. DMARD naïve patients with poor prognostic markers 
might be considered for combination therapy of MTX 
plus a biological agent 
47 (86) 10 (14) 31 (63) 18 (37) 
 
15. When adjusting treatment, factors apart from disease 
activity, such as progression of structural damage, 
comorbidities and safety concerns should be taken into 
account 
69 (97) 2 (3) 
 





Attachment II. Treat to target, differences between participating rheumatologists and 
rheumatologists that stopped during the study. 





Are you aware of the recommendations? N, % 70 (97) 2 (3) 47 (96) 2 (4) 
Are you following the recommendations?  55 (79) 15 (21) 31 (66) 16 (34) 
 
1. The primary target for treatment of rheumatoid 
arthritis should be a state of clinical remission. 
65 (93) 5 (7) 41 (93) 3 (7) 
2. Clinical remission is defined as the absence of signs and 
symptoms of significant inflammatory disease activity. 
68 (97) 2 (3) 39 (89) 5 (11) 
3. While remission should be a clear target, based on 
available evidence low disease activity may be an 
acceptable alternative 
67 (96) 3 (4) 42 (95) 2 (5) 
4. Until the desired treatment target is reached, drug 
therapy should be adjusted at least every 3 months. 
65 (93) 5 (7) 37 (84) 7 (16) 
5. Measures of disease activity must be obtained and 
documented regularly, as frequently as monthly for 
patients with high/moderate disease activity or less 
frequently (such as every 3–6 months) for patients in 
sustained low disease activity or remission 
60 (86) 10 (14) 31 (70) 13 (30) 
6. The use of validated composite measures of disease 
activity, which include joint assessments, is needed in 
routine clinical practice to guide treatment decisions. 
65 (93) 5 (7) 39 (89) 5 (11) 
7. Structural changes and functional impairment should 
be considered when making clinical decisions, in 
addition to assessing 
64 (91) 6 (9) 41 (93) 3 (7) 
8. The desired treatment target should be maintained 
throughout the remaining course of the disease. 
65 (93) 5 (7) 37 (84) 7 (16) 
9. The choice of the (composite) measure of disease activity 
and the level of the target value may be influenced by 
consideration of co-morbidities, patient factors and 
drug-related risks. 
67 (96) 3 (4) 38 (86) 6 (14) 
10. The patient has to be appropriately informed about the 
treatment target and the strategy planned to reach this 
target under the supervision of the rheumatologist. 
65 (93) 5 (7) 41 (93) 3(7) 
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In this thesis we focussed on so-called ‘treat to target’ therapy in rheumatoid arthritis (RA). 
Treat to target relies on repetitive measurements of disease activity using a composite score 
that incorporates signs of disease activity such as laboratory results, findings of physical joint 
assessments, and the opinion of the patient. It is recommended that rheumatologists intensify 
treatment when a predefined level of disease activity, the target, has not yet been achieved. 
The implementation of treatment to target in daily practice depends on the faith of the 
rheumatologist and the patient to rely on a disease activity composite index (for instance the 
DAS) rather than on some judgemental estimate of disease activity (‘the patient is doing 
well’). It also relies on a consensual opinion that a pre-set treatment target (for instance a 
DAS=<2.4, meaning low disease activity, or a DAS<1.6, meaning clinical remission) is a 
desirable as well as an achievable target, and especially on the willingness to intensify 
medication every time the treatment target has not been achieved. Several aspects of treat to 
target, in particular a plea for the improvement of the rheumatologists’ awareness about and 
the implementation of treat to target recommendations in daily clinical practice, are discussed 
in the thesis. In this chapter the content of this thesis will be summarized and the main 
findings will be discussed. 
Chapter 1 is a general introduction, which describes the characteristics of RA and the 
importance of treat to target therapy with the use of synthetic (s) DMARDs, biologic (b) 
DMARDs and corticosteroids.  
Chapter 2 offers a systematic review of national and international databases in the field of 
rheumatoid arthritis. We have found four international databases, which have started between 
2004 and 2008. They are quite similar, collecting data on patients with various degrees of 
disease severity and treated with a wide range of sDMARDs and bDMARDs.1-3 It remains 
unclear to what extent these databases are a representation of normal daily practice. The 
owners of the databases do not collaborate in the EULAR repository of databases. The 
national databases (n=32) are more heterogeneous in size, year of inception (between 1986 
and 2010), inclusion criteria, aims and frequency of data collection. Many databases share 
similarities in collecting patient-reported outcomes, physician’s clinical evaluation and 
medication use. Only half of these databases, the older and larger ones with most 
publications, are included in the EULAR repository of databases. We conclude that this 
review provides a useful overview of RA databases, which can be consulted by researchers to 
find out which databases are available for collaboration and comparisons between cohorts. 
 
 
For the future it would be valuable to be connected to the EULAR repository of databases to 
increase collaboration between researchers. Moreover, to decrease differences in set up, 
collection of data and other technical details to improve the quality of the databases. 
Chapter 3 investigates the efficacy of intra-articular injections in a treat to target strategy 
study. Patients, in whom the treatment target of low disease activity or remission has not been 
reached because of residual inflammation in one or two single joints, may sometimes be 
treated with local intra-articular (IA) glucocorticoid injections. In particular, inflamed large 
joints may have a significant effect on physical function and general wellbeing, and can often 
easily be injected with glucocorticoids. This approach has reported to be as effective as 
adding oral glucocorticoids.4 In the BeSt study, a 4-arm treat to target strategy trial in recent 
onset RA patients, intra-articular injections were optional additions to otherwise strictly 
protocolized treatment adjustments aiming at low disease activity (DAS<2.4). We found that 
intra-articular glucocorticoid injections most often resulted in short-term satisfactory 
symptom reduction but had only little impact on long-term clinical outcomes. Although not 
fully conclusive, IA injections appeared to be safe and not associated with an increase of 
local joint damage. Some previous studies have suggested that long term glucocorticoid 
treatment may prevent local radiologic joint damage.5,6 We do not know if this pertains to 
intra articular injections with glucocorticoids. Therefore, future studies are needed to confirm 
our results and to evaluate the long-term benefits and harms of IA glucocorticoid injections. 
In chapter 4 and 5 we have compared patients’- and physicians’-reported outcomes as well 
as factors that were of influence in scoring differences between patients and physicians in this 
regard. For these studies we used the METEOR database. METEOR is an online tool, which 
serves as a software program for daily practice use and can be used by rheumatologists 
worldwide to register and monitor patients in the METEOR database. The tool has been 
developed for research and practical purposes, such as to implement guidelines for RA in 
clinical practice.  
Based on data collected in the rheumatology outpatient clinic of the Leiden University 
Medical Center we have found that patients systematically rate their global disease activity 
score (GDA) higher (mean difference 11 mm on a 100 mm visual analogue scale (VAS)) than 
their physicians do; the agreement was only moderate. We found that patients base their 
decision more on subjective measures (VAS pain) while physicians value objective measures 
(SJC and ESR) as more important. We compared our results with other studies, in which we 
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found similar factors explaining PtGDA and PhGDA differences. Other studies performed in 
the United States and in Europe also described discrepancies in the agreement between 
physicians and global health assessments.7,8 These discrepancies may reflect cultural 
differences between countries with respect to disease activity assessment rated by patient and 
physician. Therefore, we have investigated the differences in rating between patient and 
physician in 13 countries (Brazil, Czech, France, Ireland, Italy, Latvia, Mexico, the 
Netherlands, Pakistan, Portugal, Spain, United Kingdom and the United States), based on the 
availability of data using the METEOR database. We found differences between PtGDA and 
PhGDA score related to country of residence of patient and physician, ranging from +13 in 
Brazil to -2 in Mexico. In some countries, these differences were related to gender 
(Netherlands and United Kingdom) and disease duration (United Kingdom and United 
States); while in other countries such a relationship was not evident. These findings raise the 
question of how important it is that patients and physicians rate disease activity similarly. 
Pain is a dominant factor in the evaluation of disease activity by the patient, but does not 
necessarily overlap with ‘objective’ signs of disease activity that dominate the physician’s 
decision. While the patient may falsely attribute the level of pain to RA-activity, the 
physician may underestimate the patient’s suffering by qualifying the RA as not very active. 
Shared decision making between patient and physician aims to fill in this gap between patient 
and physician by increasing mutual understanding.  Education is pivotal in this regard. The 
main question is: should we educate physicians how to understand the patients ‘perception’, 
or should we spend more time on teaching patients how physicians interpret their objective 
assessments? 9-11And maybe more importantly: Do these discrepancies between patients’ and 
physicians’ GDA-ratings truly affect RA care? Future research may focus on a better 
understanding of the influence of education on the behaviour of physicians and their patients 
and also on whether education improves the care for RA. 
In chapter 6 we have used the METEOR database to investigate how well DAS-steered 
therapy is applied in clinical practice, based again on data of the Leiden rheumatology 
outpatient clinic. In 69% of all visits patients were in low disease activity or remission, which 
suggests that the treat to target approach is properly followed in clinical practice. However, in 
patients with a DAS>2.4, intensification of treatment (by protocol) was applied in only 35%. 
We found that medication was less likely to be increased in patients with DAS>2.4 when 
they were treated with MTX plus a biologic DMARD, or with conventional synthetic 
DMARD monotherapy. We hypothesized that rheumatologists would not intensify treatment 
 
 
despite a DAS>2.4 when there had been a substantial improvement since the previous DAS 
measurement. But this scenario was only found in 9% of the available visits. From this study 
we conclude that, although in most of the registered visits the patients are in a state of 
remission or low disease activity, still the detection of moderate and high disease activity 
does not always lead to treatment intensification. This finding is remarkable since it is in 
violation with treat-to-target ACR/EULAR recommendations for the management of patients 
with rheumatoid arthritis, which the rheumatologists claimed to follow meticulously. It seems 
that individual patients’ circumstances rather than protocols determine if treatment guidelines 
are followed properly. In future research patients’ outcomes could be further improved, for 
instance by implementing treatment protocols with detailed instructions about how to act in 
case of a high-, a moderate- or a low DAS. Another approach to implement recommendations 
would be to increase awareness amongst rheumatologists on treat to target by means of 
educational programs, which will be discussed in the following chapter. 
In chapter 7 we described an international implementation study (IRIS), also conducted 
within METEOR, which aimed at investigating the awareness of -and improving the 
implementation of- the European League Against Rheumatism (EULAR) and treat to target 
recommendations in clinical practice. Participating rheumatologists were asked to complete a 
questionnaire on their awareness of the recommendations and they were invited to take part 
in an educational program, which included the reading of two articles and watching an 
educational video. The participants were asked to include 5-10 newly diagnosed RA patients 
in METEOR during a follow-up period of 1-2 years. During this period the participants 
received one recommendation, sent monthly by email, which intended to remind them about 
treating the patients according to the recommendations. We used the IRIS study to test 
whether the level of agreement with the recommendations is associated with their true 
application in clinical practice. For the purpose of this study we have investigated four 
recommendations and we have found that rheumatologists often report to agree with- and to 
follow these recommendations. The number of rheumatologists in the study that reported to 
comply with these recommendations varied from 82 up to 98%. On the other hand we found 
that only a moderate proportion of their patients were treated according to those same four 
recommendations: The recommendations were followed in 26-67% of the patients in the 
METEOR database. 
From this study we can conclude that agreement with a recommendation will not necessarily 
be followed by the actual application of the recommendation. The question is whether the 
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duration of our ‘intervention’ was long and profound enough to change the behaviour of the 
rheumatologists from ‘only’ agreeing with its content to actually performing it in clinical 
practice. Future research may focus on the change of behaviour of the rheumatologist over a 
longer period of time after an educational program. Also, it should be explored which other 
factors may determine the reluctance to follow recommendations. 
In addition, while setting up and conducting the study followed by collecting the data, it has 
become clear to us (Chapter 2) that there is increasing enthusiasm among rheumatologists to 
initiate databases and invest time and effort to promote therapies and/or treatment 
recommendations that may improve patient’s lives as well as advance clinical science. 
However as also suggested by the data in chapter 2, extraction of relevant data from 
databases in a format that allows analysis often is far more difficult than envisioned at the 
phase of data collection. Despite best intentions, agreements and recommendable attempts, 
technical challenges often endanger the scientific success of these initiatives. Future 
initiatives should look at advanced professional support to ensure that databases are 
developed in such a manner that they are able to provide the appropriate answers to the 
relevant questions.  
 
Conclusion and future perspectives 
We will now discuss the main goals at the beginning of this thesis and to which outcomes 
they have led, but more importantly we will discuss what we can learn from this thesis.  
The main focus was to improve care in patients with rheumatoid arthritis by investigating the 
awareness and the implementation of existing treatment-recommendations in clinical 
practice. Here we aimed at comparing rheumatologists’ agreement with - and their actual 
performance of - treat-to-target recommendations in daily clinical practice and on 
investigating (cultural) differences in perceptions of both the RA-patient and the treating 
physician in rating the global disease activity of the patient. How well are these 
recommendations implemented in daily practice and how can we further improve 
implementation of recommendations?  
Based on chapter 7, our main conclusion is that there is a discrepancy between the 
rheumatologists’ agreement and will to follow recommendations and the actual application of 
recommendations in clinical practice. It seems that rheumatologists are willing to apply 
guidelines, but that there are still certain factors that inhibit them to follow recommendations 
 
 
in individual patients. What can we do to reduce the gap between agreement with 
recommendations and behaviour in clinical practice? 
We may want to investigate the effects of implementation initiatives, such as educational 
programs, meetings or reminders by email and/or telephone. In follow up studies of IRIS we 
will evaluate the benefits of stimulated training by an educational program on the application 
of guidelines in RA. However, to actually change the rheumatologist’s behaviour we may 
also want to focus on reasons that hinder rheumatologists to follow recommendations in 
clinical practice. This may well be related to differences between patients’ and 
rheumatologists’ perspectives on the disease as we have observed in chapter 4. Here we have 
found that patients and physicians think about different determinants when assessing global 
disease activity. Patients put more weight on pain and physicians more on ESR and swollen 
joint count, which may easily jeopardise so called ‘shared decision making’ between patients 
and rheumatologists. In order to promote better agreement between patients and 
rheumatologists we should focus future research on investigating to what extent treatment 
goals for rheumatologists and patients differ and why. Interestingly, agreement between 
rheumatologist and patient about the severity of RA may be dependent on the country in 
which patient and physician both reside as has been suggested in chapter 5. Here we have 
found that the agreement between the patient and the physician regarding the assessment of 
global disease activity differs per country; Shared decision making, a common term, may 
have different cultural implications!  
We hypothesize that improving the agreement between patient and physician on the activity 
of the disease will lead to better performance in clinical practice. Shared decision making 
may be enhanced if the rheumatologist communicates well with the patient on desirable and 
realistic target achievements. For instance, the rheumatologist and the patient can agree on a 
treatment target of DAS low disease activity when remission is not realistic. 
In chapter 6 we have observed that patients with high levels of disease activity are not 
always receiving the recommended treatment in daily practice. Reasons for this can be 
related to the physician: For instance, the rheumatologist may value the patient’s will not to 
change treatment, as suggested in chapter 6. But also the complexity of RA and the 
increasing number of treatment options may make it difficult to decide for a rheumatologist 
which approach is the best to choose. Furthermore, the rheumatologist may believe that a 
slightly elevated level of disease activity does not justify rigorous treatment change. 
On the other hand, the patient may be reluctant to intensify the medication thus following 
recommendations that she is not familiar with. Patients may, for instance, better accept 
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they have led, but more importantly we will discuss what we can learn from this thesis.  
The main focus was to improve care in patients with rheumatoid arthritis by investigating the 
awareness and the implementation of existing treatment-recommendations in clinical 
practice. Here we aimed at comparing rheumatologists’ agreement with - and their actual 
performance of - treat-to-target recommendations in daily clinical practice and on 
investigating (cultural) differences in perceptions of both the RA-patient and the treating 
physician in rating the global disease activity of the patient. How well are these 
recommendations implemented in daily practice and how can we further improve 
implementation of recommendations?  
Based on chapter 7, our main conclusion is that there is a discrepancy between the 
rheumatologists’ agreement and will to follow recommendations and the actual application of 
recommendations in clinical practice. It seems that rheumatologists are willing to apply 
guidelines, but that there are still certain factors that inhibit them to follow recommendations 
 
 
in individual patients. What can we do to reduce the gap between agreement with 
recommendations and behaviour in clinical practice? 
We may want to investigate the effects of implementation initiatives, such as educational 
programs, meetings or reminders by email and/or telephone. In follow up studies of IRIS we 
will evaluate the benefits of stimulated training by an educational program on the application 
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rheumatologists’ perspectives on the disease as we have observed in chapter 4. Here we have 
found that patients and physicians think about different determinants when assessing global 
disease activity. Patients put more weight on pain and physicians more on ESR and swollen 
joint count, which may easily jeopardise so called ‘shared decision making’ between patients 
and rheumatologists. In order to promote better agreement between patients and 
rheumatologists we should focus future research on investigating to what extent treatment 
goals for rheumatologists and patients differ and why. Interestingly, agreement between 
rheumatologist and patient about the severity of RA may be dependent on the country in 
which patient and physician both reside as has been suggested in chapter 5. Here we have 
found that the agreement between the patient and the physician regarding the assessment of 
global disease activity differs per country; Shared decision making, a common term, may 
have different cultural implications!  
We hypothesize that improving the agreement between patient and physician on the activity 
of the disease will lead to better performance in clinical practice. Shared decision making 
may be enhanced if the rheumatologist communicates well with the patient on desirable and 
realistic target achievements. For instance, the rheumatologist and the patient can agree on a 
treatment target of DAS low disease activity when remission is not realistic. 
In chapter 6 we have observed that patients with high levels of disease activity are not 
always receiving the recommended treatment in daily practice. Reasons for this can be 
related to the physician: For instance, the rheumatologist may value the patient’s will not to 
change treatment, as suggested in chapter 6. But also the complexity of RA and the 
increasing number of treatment options may make it difficult to decide for a rheumatologist 
which approach is the best to choose. Furthermore, the rheumatologist may believe that a 
slightly elevated level of disease activity does not justify rigorous treatment change. 
On the other hand, the patient may be reluctant to intensify the medication thus following 
recommendations that she is not familiar with. Patients may, for instance, better accept 





additional treatments with local corticosteroids in inflamed joints (chapter 3) that may 
provide short-term relief, and as such in agreement with principles of treat-to-target, but still 
with uncertain long term consequences. 
Implementation research, studies on how recommendations will be adopted and applied in 
clinical practice, is of pivotal importance to further improve clinical practice. Consulting 
platforms such as the EULAR repository of databases discussed in chapter 2, containing a 
lot of information about various databases in Europe, with its aim to improve collaboration 
between researchers, but also initiatives such as METEOR (described in Chapter 4 - 7), with 
aggregated information available about thousands of patients from all over the world, could 
be of help with this.  
Since only half of the identified European databases are connected to EULAR repository 
awareness among researchers should be promoted and a worldwide initiative for a repository 
of databases would be worthwhile to stimulate in the future. 
In conclusion, to improve care in patients with rheumatoid arthritis we should seek for 
effective strategies to better implement recommendations in clinical practice. In addition, we 
should try to optimize shared decision making between rheumatologists and physicians by 
improving communication between them with regard to achievable treatment targets. Future 
studies, such as IRIS, will be carried out to prove whether implementation strategies, such as 
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In dit proefschrift staat ‘treat to target’ therapie voor patiënten met reumatoïde artritis (RA) 
centraal. Het ‘treat to target’ concept berust op het maken van frequente en betrouwbare 
schattingen van de ziekteactiviteit aan de hand van scores van labwaarden, mate van 
gewrichtsklachten en de mening van de patiënt. Het is van belang dat reumatologen de 
patiënten frequent monitoren en de therapie aanpassen wanneer van tevoren gedefinieerde 
behandeldoelen met betrekking tot de ziekteactiviteit nog niet zijn behaald. De implementatie 
van ‘treat to target’ in de dagelijks praktijk is sterk afhankelijk van het vertrouwen van de 
reumatoloog en patiënt in de huidige maten voor de ziekteactiviteit, zoals bijvoorbeeld de 
DAS (“Disease Activity Score”), en de meerwaarde van zo’n score boven het (subjectieve) 
oordeel van de arts (“het gaat goed met de patiënt”). Daarnaast is implementatie afhankelijk 
van het behandeldoel. Men kan zich bijvoorbeeld richten op het bereiken van een DAS=<2.4 
(lage ziekte activiteit) of een DAS=<1.6 (remissie, dat wil zeggen geen ziekteactiviteit 
meetbaar). De echte vraag is: Welk behandeldoel is wenselijk en haalbaar, en in hoeverre zijn 
reumatologen en patiënten bereid om zo nodig vergaande intensivering van behandeling te 
accepteren wanneer het doel niet behaald is. In dit proefschrift zullen verschillende aspecten 
van ‘treat to target’ toegelicht worden. Hierbij staan het vergroten van het bewustzijn- en de 
implementatie van de ‘treat to target’ richtlijnen onder reumatologen in de dagelijkse praktijk 
centraal. In dit hoofdstuk zal de inhoud van dit proefschrift worden samengevat met de 
belangrijkste resultaten en de conclusie.  
Hoofdstuk 1 is een algemene introductie waarin karakteristieken van RA worden 
beschreven. Daarnaast wordt het belang van ‘treat tot target’ therapie en het gebruik van 
conventionele synthetische ‘disease-modifying antirheumatic drugs’ (cs) DMARDs, 
biologische (b) DMARDs en corticosteroïden toegelicht.  
In hoofdstuk 2 worden de resultaten beschreven van een systematisch literatuuronderzoek 
naar bestaande inter(nationale) databases in reumatoïde artritis. Het literatuuronderzoek 
leverde vier internationale databases op die recent (tussen 2004 en 2008) zijn opgericht en de 
volgende gemeenschappelijke eigenschappen bezitten: ze verzamelen data van patiënten in 
alle stadia van RA die worden behandeld met een grote verscheidenheid aan csDMARDs en 
bDMARDs. Het is nog niet duidelijk in hoeverre deze databases de dagelijkse praktijk 
reflecteren. De beheerders van de databases zijn niet aangesloten bij de ‘EULAR (European 
Leage Against Rheumatism) repository of databases’, een initiatief gestart door de EULAR 
 
 
met als doel om de samenwerking tussen Europese onderzoekers te verbeteren. In de 
nationale databases (n=32) zijn meer verschillen gevonden dan in de internationale databases. 
De nationale databases verschillen in grootte, jaar van oprichting (tussen 1986 en 2010), 
inclusiecriteria, doelen en de frequentie van dataverzameling. De meeste nationale databases 
hebben ook gemeenschappelijke eigenschappen, zoals het rapporteren van patiënt-
gerapporteerde uitkomsten, medicatiegebruik en de klinische evaluatie van de arts. Slechts de 
helft van deze 32 databases, de oudere en grotere, zijn aangesloten bij de ‘EULAR repository 
of databases’. Dit literatuuronderzoek geeft een bruikbaar overzicht van RA databases dat 
kan worden geraadpleegd door onderzoekers om te weten welke databases er bestaan en welk 
soort onderzoek er gedaan wordt. Onderzoekers kunnen op deze manier samenwerken en 
bijvoorbeeld cohorten met elkaar vergelijken. Het zou waardevol zijn als er in de toekomst 
meer databases zijn verbonden met de ‘EULAR repository of databases’. Door meer en 
betere samenwerking zal de kwaliteit van de databases verbeteren en de verschillen tussen de 
databases in o.a. onderzoeksopzet, het verzamelen van data en andere technische details, 
kleiner worden. 
In hoofdstuk 3 wordt de relatie tussen intraarticulaire (IA) injecties en klinische 
uitkomstmaten in een ‘treat to target’ setting beschreven. Het komt soms voor dat patiënten 
geen lage ziekte activiteit of remissie kunnen bereiken omdat er nog één of twee gewrichten 
ontstoken zijn. Met name een ontsteking van de grote gewrichten kan invloed hebben op het 
dagelijks functioneren en het algemeen welbevinden. Deze gewrichten kunnen gemakkelijk 
lokaal geïnjecteerd worden met corticosteroïden, hetgeen net zo effectief is als het oraal 
toedienen van corticosteroïden. BeSt is een gerandomiseerde studie waarin patiënten werden 
toegewezen aan vier verschillende behandelarmen. In deze studie was het toegestaan om IA-
injecties toe te dienen wanneer nodig. In BeSt zijn patiënten behandeld volgens een strict 
protocol waarin behandeling werd gestuurd op het bereiken van een lage ziekteactiviteit 
(DAS<2.4). Uit deze studie is gebleken dat IA-injecties met corticosteroïden op korte termijn 
meestal tot verlichting van ontstekingsklachten leidt, maar op lange termijn is er maar weinig 
invloed op klinische uitkomstmaten. We vonden geen relatie tussen IA injecties en 
gewrichtsschade. Daaruit kunnen we niet concluderen dat IA injecties schade kunnen 
voorkomen.Toekomstig onderzoek moet zich richten op het bevestigen van onze resultaten 
en op het evalueren van de voor- en nadelen van IA-injecties met corticosteroïden op lange 
termijn. 
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In hoofdstuk 4 en 5 zijn patient- en arts gerapporteerde uitkomstmaten met elkaar vergeleken 
en is onderzocht welke factoren invloed hebben op het verschil tussen deze uitkomstmaten.  
Deze studie is uitgevoerd in de METEOR database, een online programma dat gebruikt kan 
worden door reumatologen in de dagelijkse praktijk om patiënten te registreren en te 
monitoren. METEOR is ontwikkeld voor zowel onderzoeksdoeleinden als om praktische 
redenen, zoals bijvoorbeeld het implementeren van richtlijnen voor RA in de klinische 
praktijk. Uit data van het Leids Universitair Medisch centrum (LUMC) in de METEOR 
database is gebleken dat de patiënt zijn eigen globale ziekteactiviteit (GDA) hoger scoort dan 
zijn arts dat doet. Het verschil tussen beide scores is gemiddeld 11mm op een visuele analoge 
schaal (VAS): de overeenkomst tussen patiënt en reumatoloog is matig. Uit deze studie is ook 
gebleken dat patiënten hun GDA score vooral baseren op subjectieve (pijn) maten en dat 
reumatologen objectieve (gezwollen gewrichten en bloedbezinking) maten belangrijker 
vinden. Vroegere studies hebben ook laten zien dat bovengenoemde factoren de verschillen 
in GDA score tussen patiënt en arts lijken te verklaren. Daarnaast zijn er in Europa en de 
Verenigde Staten studies uitgevoerd met andere globale gezondheidsscores die ook hebben 
aangetoond dat er verschillen zijn tussen patiënt en arts wat betreft de beoordeling van die 
score. Deze discrepanties tussen patiënt en arts zullen wellicht te wijten zijn aan culturele 
verschillen tussen landen. Om die reden hebben we de verschillen in GDA score tussen 
patiënt en arts onderzocht in 13 verschillende landen (Brazilië, Tsjechië, Frankrijk, Ierland, 
Italië, Letland, Mexico, Nederland, Pakistan, Portugal, Spanje, Verenigd Koninkrijk en de 
Verenigde Staten) gebaseerd op beschikbare data in de METEOR database. De discrepantie 
in GDA score tussen patiënt en arts varieërde per land: van +13mm tussen patiënten en artsen 
wonend in Brazilië tot -2mm tussen patiënten en artsen wonend in Mexico. In sommige 
landen waren deze verschillen gerelateerd aan geslacht (Nederland en Verenigd Koninkrijk) 
en ziekteduur (Verenigd Koninkrijk en Verenigde Staten), terwijl in andere landen dergelijke 
relaties niet werden gevonden. Het is natuurlijk de vraag hoe belangrijk het is dat patiënten 
en artsen dezelfde score geven aan de ziekteactiviteit. Voor de patiënt heeft pijn een 
belangrijke bijdrage in de evaluatie van ziekteactiviteit, maar de mate van pijn hoeft niet 
persé overeen te komen met de objectieve kernmerken van de ziekteactiviteit die  beoordeeld 
worden door de arts. Terwijl de patiënt de RA activiteit wellicht zal overschatten (omdat 
hij/zij veel pijn heeft), zal de arts deze eerder onderschatten als objectieve verschijnselen 
ontbreken. Het gezamenlijk maken van beslissingen tussen patiënt en arts heeft als doel de 
verschillen in interpretatie tussen patiënt en arts te verkleinen zodat ze elkaar beter leren 
begrijpen. Dit kan bevorderd worden door educatie. De vragen die hieruit volgen zijn: 
 
 
Moeten we artsen onderwijzen in het beter leren begrijpen van de interpretatie van de patiënt, 
of moeten we meer tijd spenderen aan het onderwijzen van patiënten in het leren begrijpen 
hoe artsen objectieve maten interpreteren? En in welke mate hebben de verschillen in de 
beoordeling van ziekteactiviteit tussen patiënt en arts een invloed op de zorg voor patiënten 
met RA? Toekomstig onderzoek zou zich kunnen richten op het beter leren begrijpen van de 
invloed van educatie op het gedrag van artsen en hun patiënten. Daarnaast zou onderzocht 
kunnen worden of dergelijke educatie de zorg van RA verbetert.  
In hoofdstuk 6 wordt geëvalueerd hoe goed DAS gestuurd behandelen in de dagelijkse 
praktijk wordt toegepast. Voor deze studie werd gebruik gemaakt van METEOR data en 
wederom is een subselectie gemaakt van patiënten die behandeld zijn in het LUMC. Uit deze 
studie bleek dat in 69% van de gerapporteerde visites in METEOR, patiënten een lage 
ziekteactiviteit hadden. Dit resultaat wekt de suggestie dat behandelen volgens het ‘treat to 
target’ concept wel wordt toegepast in de klinische praktijk. Echter, tijdens visites waar 
patiënten een matige- of hoge ziekteactiviteit (DAS>2.4) hadden, werd de therapie in slechts 
35% aangepast, terwijl dit volgens de richtlijnen wel wordt aanbevolen. Patiënten bij wie de 
therapie niet werd aangepast ondanks een DAS>2.4, ontvingen vaker therapie met MTX en 
een bDMARD, of csDMARD monotherapie. Een reden hiervoor zou kunnen zijn dat de 
reumatoloog besluit de medicatie niet op te hogen in deze patiëntengroep, omdat hij/zij een 
substantiële verbetering ziet ten opzichte van de vorige DAS meting. Echter, dit scenario was 
bij slechts 9% van de patiëntvisites waargenomen. Uit dit onderzoek kunnen we concluderen 
dat patiënten tijdens de meeste visites een lage ziekte activiteit hebben of in remissie zijn. De 
medicatie wordt echter lang niet altijd opgehoogd in patiënten met matige- of hoge ziekte 
activiteit. Dit resultaat is opmerkelijk omdat het niet in overeenstemming is met de EULAR 
richtlijnen voor de management van RA, die er natuurlijk voor bedoeld zijn om te worden 
nageleefd door de reumatoloog. Het is mogelijk dat individuele omstandigheden van de 
patiënt een grotere invloed hebben op het naleven van richtlijnen dan specifieke 
behandelprotocols. In toekomstig onderzoek zouden de klinische uitkomstmaten van de 
patiënt verbeterd kunnen worden door gedetailleerde behandelprotocollen te implementeren 
waar instructies in staan beschreven over hoe te handelen bij een patiënt met hoge, matige en 
lage zieteactiviteit. Een andere manier om richtlijnen te implementeren is door reumatologen 
te stimuleren zich bewust te worden van ‘treat to target’. Dit zou kunnen door middel van 
educatie waar we in het volgende hoofdstuk dieper op in zullen gaan. 
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In hoofdstuk 7 staan de resultaten van een studie naar internationale implementatie van 
richtlijnen (IRIS) beschreven, welke ook is uitgevoerd in de METEOR database. Deze studie 
had als doel om de bewustwording en de implementatie van de EULAR richtlijnen voor de 
behandeling van RA en de ‘treat to target’ richtlijnen te onderzoeken en te verbeteren. 
Deelnemende reumatologen werd gevraagd om een vragenlijst in te vullen over of ze de 
richtlijnen kennen en of ze deze in de dagelijkse praktijk toepassen. Vervolgens werden ze 
uitgenodigd om deel te nemen aan een educatief programma, waarbij ze ze twee artikelen 
moesten lezen en een educatie-video moesten bekijken. Daarna werd de deelnemers gevraagd 
om 5-10 ‘nieuw gediagnosticeerde’ RA patiënten toe te voegen aan de METEOR database 
gedurende een follow-up periode van 1-2 jaar. Tijdens deze periode ontvingen deelnemende 
reumatologen maandelijks een email waarin één van de aanbevelingen uit de richtlijnen werd 
toegelicht. Deze email was bedoeld om reumatologen te stimuleren patiënten volgens de 
richtlijnen te behandelen. In de IRIS studie hebben we onderzocht of reumatologen die 
rapporteren dat zij patiënten behandelen volgens de richtlijnen dit ook daadwerkelijk doen in 
de dagelijkse praktijk. Hierbij zijn vier aanbevelingen uit de richtlijnen nader onderzocht. Uit 
de resultaten van dit onderzoek blijkt dat reumatologen in 82-98% van de gevallen 
rapporteren dat ze deze vier aanbevelingen inderdaad opvolgen. We vonden echter in de 
METEOR database dat er slechts een berperkt percentage van hun patiënten (26-67%) 
daadwerkelijk volgens deze vier aanbevelingen werden behandeld. Uit deze studie 
concludeerden we dan ook dat wanneer men rapporteert een richtlijn op te volgen dit niet 
betekent dat men deze richtlijn ook daadwerkelijk opvolgt in de dagelijkse praktijk. De vraag 
is dan ook of ons ‘educatie-programma’ voldoende impact heeft gehad om het gedrag van de 
reumatoloog te veranderen van ‘het eens zijn met een aanbeveling’ tot ‘het daadwerkelijk 
toepassen van de aanbeveling’ in de klinische praktijk. In de toekomst zou onderzocht 
moeten worden welke factoren van invloed zijn op het niet opvolgen van richtlijnen. Uit 
hoofdstuk 2 is duidelijk geworden dat er enthousiasme onder reumatologen is om databases 
op te richten en therapieën/richtlijnen te promoten, hetgeen kan leiden tot verbetering van 
klinisch onderzoek en patiëntenzorg. In hoofdstuk 2 is echter ook gebleken dat het moeilijk 
is om relevante informatie voor analyses uit deze databases te halen, aangezien hier 
onvoldoende op wordt geanticipeerd in de fase van dataverzameling. Ondanks de beste 
bedoelingen blijven er technische uitdagingen om deze databases tot een wetenschappelijk 
succes te maken. Toekomstige initiatieven zouden zich kunnen richten op het verbeteren van 
de ontwikkeling van databases, zodat we op een efficiëntere manier relevante 
onderzoeksvragen kunnen beantwoorden. 
 
 
Conclusie en toekomstperspectieven 
Dit proefschrift richtte zich op het verbeteren van zorg bij patiënten met reumatoïde artritis, 
met name door het bewustzijn en de implementatie van bestaande richtlijnen in de dagelijkse 
praktijk te onderzoeken en waar mogelijk te verbeteren. Hierbij hebben we onderzocht of 
reumatologen die het eens zijn met de richtlijnen ze ook daadwerkelijk toepassen in klinische 
praktijk. Daarnaast hebben we (culturele) verschillen bestudeerd in de perceptie van 
ziekteactiviteit van patiënt versus arts. Hoe goed zijn huidige richtlijnen al geïmplementeerd 
in de klinische praktijk en hoe kunnen we de implementatie  verder verbeteren? Kortom, wat 
kunnen we leren van dit proefschrift? 
Onze belangrijkste conclusie is dat er een discrepantie is tussen het eens zijn met- en het 
opvolgen van- richtlijnen door reumatologen in de dagelijkse praktijk. Het lijkt erop dat 
reumatologen de richtlijnen graag willen opvolgen maar dat er factoren zijn die hen 
belemmeren om ze ook daadwerkelijk toe te passen. Wat kunnen we doen om de kloof tussen 
het eens zijn met richtlijnen en gedrag in klinische praktijk te verkleinen? We zouden kunnen 
onderzoeken wat de effecten zijn van implementatie initiatieven zoals educatieve  
programma’s, meetings of reminders per e-mail en/of telefoon. In vervolg studies van de 
IRIS zullen we evalueren welke de voordelen zijn van het volgen van een educatief 
programma met betrekking tot het opvolgen van richtlijnen. Echter, om het gedrag van 
reumatologen daadwerkelijk te beïnvloeden  zullen we ons moeten richten op factoren die de 
reumatoloog belemmeren om richtlijnen op te volgen in dagelijkse praktijk. Die kunnen 
bijvoorbeeld gerelateerd zijn aan verschillen in perceptie van ziekteactiviteit tussen patiënt en 
reumatoloog, zoals is gebleken uit de resultaten in hoodstuk 4. Hier hebben we gevonden dat 
bij het beoordelen van de ziekteactiviteit patiënt en reumatoloog niet met dezelfde factoren 
rekening houden. De patiënt laat zich meer leiden door pijn en de reumatoloog meer door  
bloedbezinking en gezwollen gewrichten. Dit verschil kan een negatieve invloed hebben op 
het maken van gezamenlijke beslissingen door patiënt en reumatoloog. Om de 
overeenstemming tussen de patiënt en arts te vergroten zou toekomstig onderzoek zich 
moeten richten op verschillen in behandeldoel van zowel  patiënt als arts en op waarom 
dergelijke verschillen bestaan. Zo zou het kunnen zijn dat de mate van overeenstemming in 
ziekteactiviteit afhankelijk is van het land van herkomst. Uit hoofdstuk 5 is gebleken dat 
overeenstemming verschilt per land. Het gezamenlijk beslissingen nemen (zoals wordt 
gepropageerd) zou dus culturele connotaties kunnen hebben. De impliciete verwachting is dat 
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een verbetering in overeenstemming tussen de patiënt en arts in het beoordelen van de 
ziekteactiviteit zal leiden tot een betere patiëntenzorg in de dagelijkse praktijk. Het proces 
van gezamenlijk beslissingen nemen zou kunnen worden verbeterd door een goede 
communicatie tussen patiënt en arts over gewenste en realistische behandeldoelen. Wanneer 
remissie niet haalbaar is kunnen de patiënt en reumatoloog gezamenlijk beslissen om 
bijvoorbeeld het bereiken van lage ziekteactiviteit tot doel te stellen. Uit hoofdstuk 6 is 
gebleken dat patiënten met matige tot hoge ziekteactiviteit niet altijd werden behandeld 
volgens de richtlijnen. Zowel arts- als patiënt-gerelateerde factoren kunnen hierbij een 
invloed hebben gehad. De reumatoloog kan moeite hebben met het kiezen van de juiste 
aanpak, aangezien er veel verschillende behandelopties zijn en RA een complexe ziekte is. 
Ook kan de reumatoloog het niet eens zijn met de DAS en er dan voor kiezen om bij een licht 
verhoogde ziekteactiviteit niet meteen de behandeling aan te passen. Aan de andere kant kan 
het de wens zijn van de patiënt om de therapie niet op te hogen. Sommige patiënten hebben 
vervolgens meer baat bij injectie van lokale ontstoken gewrichten met corticosteroïden. Deze 
injecties verminderen klachten op korte termijn, maar op lange termijn weten we nog niet 
goed wat de consequenties kunnen zijn (hoofdstuk 3). Om de behandeling van RA in de 
dagelijkse praktijk te verbeteren is het van belang om te onderzoeken hoe goed richtlijnen 
reeds worden toegepast in dagelijkse praktijk en hoe we dit verder kunnen verbeteren. 
Platforms, zoals de EULAR repository of databases (hoofdstuk 2), kunnen hierbij van dienst 
zijn omdat ze veel informatie bevatten over verscheidene databases in Europa en als doel 
hebben de samenwerking tussen reumatologen te verbeteren. Daarnaast kunnen initiatieven 
zoals METEOR, dat gegevens bevat over duizenden patiënten wereldwijd, helpen om 
richtlijnen beter te implementeren. Uit ons literatuuronderzoek is gebleken dat slechts de helft 
van de Europese databases is aangesloten bij de EULAR repository of databases. Daarom is 
het van belang onderzoekers te stimuleren hieraan deel te nemen. Ook zou het waardevol zijn 
om in de toekomst een ‘repository of databases’ op te richten waaraan onderzoekers van 
overal in de wereld kunnen deelnemen. 
Tot slot, om de zorg voor patiënten met reumatoïde artritis te verbeteren, moeten we op zoek 
gaan naar effectieve strategieën om richtlijnen beter te implementeren in de klinische 
praktijk. Daarnaast moeten we stimuleren dat klinische beslissingen gezamenlijk door patiënt 
en reumatoloog worden gemaakt door onderlinge communicatie met betrekking tot haalbare 
behandeldoelen te bevorderen. Toekomstig onderzoek, zoals de IRIS, zal zich richten op 
strategieën die tot doel hebben de implementatie van  richtlijnen te verbeteren en zodoende 
de zorg voor patiënten met reumatoïde artritis in de klinische praktijk te optimaliseren.
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een verbetering in overeenstemming tussen de patiënt en arts in het beoordelen van de 
ziekteactiviteit zal leiden tot een betere patiëntenzorg in de dagelijkse praktijk. Het proces 
van gezamenlijk beslissingen nemen zou kunnen worden verbeterd door een goede 
communicatie tussen patiënt en arts over gewenste en realistische behandeldoelen. Wanneer 
remissie niet haalbaar is kunnen de patiënt en reumatoloog gezamenlijk beslissen om 
bijvoorbeeld het bereiken van lage ziekteactiviteit tot doel te stellen. Uit hoofdstuk 6 is 
gebleken dat patiënten met matige tot hoge ziekteactiviteit niet altijd werden behandeld 
volgens de richtlijnen. Zowel arts- als patiënt-gerelateerde factoren kunnen hierbij een 
invloed hebben gehad. De reumatoloog kan moeite hebben met het kiezen van de juiste 
aanpak, aangezien er veel verschillende behandelopties zijn en RA een complexe ziekte is. 
Ook kan de reumatoloog het niet eens zijn met de DAS en er dan voor kiezen om bij een licht 
verhoogde ziekteactiviteit niet meteen de behandeling aan te passen. Aan de andere kant kan 
het de wens zijn van de patiënt om de therapie niet op te hogen. Sommige patiënten hebben 
vervolgens meer baat bij injectie van lokale ontstoken gewrichten met corticosteroïden. Deze 
injecties verminderen klachten op korte termijn, maar op lange termijn weten we nog niet 
goed wat de consequenties kunnen zijn (hoofdstuk 3). Om de behandeling van RA in de 
dagelijkse praktijk te verbeteren is het van belang om te onderzoeken hoe goed richtlijnen 
reeds worden toegepast in dagelijkse praktijk en hoe we dit verder kunnen verbeteren. 
Platforms, zoals de EULAR repository of databases (hoofdstuk 2), kunnen hierbij van dienst 
zijn omdat ze veel informatie bevatten over verscheidene databases in Europa en als doel 
hebben de samenwerking tussen reumatologen te verbeteren. Daarnaast kunnen initiatieven 
zoals METEOR, dat gegevens bevat over duizenden patiënten wereldwijd, helpen om 
richtlijnen beter te implementeren. Uit ons literatuuronderzoek is gebleken dat slechts de helft 
van de Europese databases is aangesloten bij de EULAR repository of databases. Daarom is 
het van belang onderzoekers te stimuleren hieraan deel te nemen. Ook zou het waardevol zijn 
om in de toekomst een ‘repository of databases’ op te richten waaraan onderzoekers van 
overal in de wereld kunnen deelnemen. 
Tot slot, om de zorg voor patiënten met reumatoïde artritis te verbeteren, moeten we op zoek 
gaan naar effectieve strategieën om richtlijnen beter te implementeren in de klinische 
praktijk. Daarnaast moeten we stimuleren dat klinische beslissingen gezamenlijk door patiënt 
en reumatoloog worden gemaakt door onderlinge communicatie met betrekking tot haalbare 
behandeldoelen te bevorderen. Toekomstig onderzoek, zoals de IRIS, zal zich richten op 
strategieën die tot doel hebben de implementatie van  richtlijnen te verbeteren en zodoende 
de zorg voor patiënten met reumatoïde artritis in de klinische praktijk te optimaliseren.
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